Vector used for preparing circular RNA and method

By screening introns with high self-splicing ability and optimizing vector structure, efficient preparation of circular RNA was achieved, solving the problems of low circularization efficiency and high cost, and improving the yield and stability of circular RNA.

WO2024240260A1PCT designated stage expired Publication Date: 2024-11-28NANJING GENSCRIPT BIOTECH CO LTD

Patent Information

Application Number
PCT/CN2024/095316
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-11
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing circular RNA preparation technologies have low circularization efficiency, resulting in reduced yield and increased production costs. Furthermore, the complex process flow makes it difficult to meet the demand for efficient circular RNA preparation.

Method used

By screening introns with high self-splicing ability, such as class I introns from Bacillus anthracis, Coxiella behnea, and Synestomyces, the homologous arm structure in the circular RNA preparation vector was optimized, and circularization was achieved during in vitro transcription, simplifying the process and improving the circularization efficiency.

Benefits of technology

It improves the circularization efficiency of circular RNA, reduces process residues, lowers production costs, and enhances the yield and stability of circular RNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024095316-APPB-I100001
    Figure PCTCN2024095316-APPB-I100001
  • Figure PCTCN2024095316-APPB-I100002
    Figure PCTCN2024095316-APPB-I100002
  • Figure PCTCN2024095316-APPB-I100003
    Figure PCTCN2024095316-APPB-I100003
Patent Text Reader

Abstract

The present invention relates to a vector used for preparing a circular RNA, said vector comprising: a) an optional 5' homologous arm, b) a 3' self-splicing intron fragment containing a 3' splice site, c) an optional 5' intervening sequence, d) an optional internal ribosome entry site (IRES) encoding sequence, e) a target gene, f) an optional 3' intervening sequence, g) a 5' self-splicing intron fragment containing a 5' splice site, and h) an optional 3' homologous arm, said elements being operatively connected in sequence. The 3' self-splicing intron fragment containing the 3' splice site and the 5' self-splicing intron fragment containing the 5' splice site are derived from introns of the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Scytonema hofmanni, the tRNA-fMet gene of Synechocystis sp., the 23S rRNA gene of Thermotoga naphthophila, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga subterranea.
Need to check novelty before this filing date? Find Prior Art

Description

Vectors and methods for preparing circular RNA Cross-references The present invention claims priority to Chinese patent applications No. 2023105975929 filed on May 24, 2023 and No. 2023110189536 filed on August 11, 2023, the entire contents of which are incorporated herein by reference. Field of the Invention The present application relates to the field of molecular biology and bioengineering technology, and in particular to a DNA vector for preparing circular RNA, a circularizable RNA molecule and a circular RNA molecule. Background Art With technological breakthroughs, RNA therapy has developed into a new area of ​​great potential in the biopharmaceutical industry, including the use of messenger RNA (mRNA), small interfering RNA (siRNA) and micro RNA (miRNA). For example, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was widely prevalent in the world not long ago [1,2] , which has attracted people's attention and given people hope. The rapid overall process of mRNA design, production and testing is undoubtedly a new and potential medical approach for responding to urgent and rapidly mutating virus types. With the success of mRNA drugs, the method of converting mRNA into circular RNA (circRNA) to prolong the duration of protein translation has aroused great interest. Previous methods to improve mRNA stability mainly started from simulating the structure of natural mRNA, including the use of untranslated regions, methylguanosine cap analogs, nucleoside modifications and codon optimization, which improved mRNA stability to a certain extent. [3,4–7] Since circRNA has natural structural advantages, it is theoretically desirable to use it as an alternative method to improve RNA stability. circRNA is a type of closed circular single-stranded RNA molecule that is covalently linked from head to tail. [8] Recently, it has been found that it is widely present in eukaryotes mainly in the form of non-coding RNA. [9,10,11] , and most of the discovered circRNAs are produced by trans-splicing [12–14] With the discovery of more and more circRNAs, researchers have proposed that some specific circRNA molecules also have protein coding functions. [15,16] In addition, researchers have demonstrated that circRNAs can be translated both in vivo and in vitro with the addition of an internal ribosome entry site (IRES). [8,10,14]Compared with mRNA, circRNA is end-to-end and lacks 5' and 3' ends, so it has a stronger ability to resist exonuclease degradation and has a longer half-life. [12,17] Some scholars have tried to circularize synthetic long linear transcripts into circRNAs. [10,14] , and has made considerable progress. The splicing and removal of most introns requires the interaction of multiple proteins, but there are also some special introns that are removed by self-splicing. These introns with self-splicing functions can be divided into two categories based on their structure and splicing mechanism: Class I and Class II. The processing of Class I introns is initiated by an ester exchange reaction mediated by exogenous guanosine cofactor (GTP). [18,19] The splicing of class II introns is similar to that of eukaryotic mRNA precursors, in which the 5' splice site is attacked by the -OH group of the nucleotide protruding from the branch site, first generating an intronic lariat structure. Subsequently, the -OH released from the 5' exon attacks the 3' splice site, ultimately splicing the two exons together. [19,20] Using the self-splicing function of class I and class II introns, the researchers designed the sequence to split the self-splicing intron into two halves, which were loaded onto the two ends of the target circularized RNA sequence, respectively, and the circularization of the target sequence was achieved through in vitro catalysis. [21-24] Since circular RNA has two covalently closed ends and no exposed 5' end, there is no cap structure to initiate RNA translation. In order to solve the problem of circular RNA translation, researchers screened and used ribosome entry site sequences (IRES) and successfully synthesized circular RNA with stable translation function in vitro. Daniel G. Anderson et al. [21-24] The in vitro circularization of RNA is achieved by utilizing the self-splicing function of the intron of class I introns, such as the pre-tRNA-Leu gene of Anabaena or the T4 bacteriophage Td gene (T4td), in which the circularization ability of this intron is relatively superior. In the production process of circular RNA, the efficiency of circularization has a crucial impact on the yield, purity and cost of circRNA. High circularization efficiency can reduce the amount of enzyme used, thereby reducing production costs and process residues. However, the current circularization efficiency still has room for improvement. The citation of any document in this application does not constitute an admission that these documents are prior art to this application. Summary of the invention The inventors of the present application have studied and improved the circular RNA preparation technology from multiple aspects, including screening new introns with in vitro self-splicing ability, optimizing the homologous arms of circular RNA preparation vectors, and optimizing the production process. This not only improves the RNA cyclization efficiency, but also reduces the preparation steps, which will have a positive impact on increasing circRNA production, controlling costs, and reducing process residues. First, the inventors of the present application screened introns from various organisms and found that introns from Bacillus Anthraci., Coxiella burnetii., Scytonema hofmanii, Synechocystis sp., Thermotoga naphthophila., Synechococcus elongatus or Thermotoga subterranea, specifically from the recA gene of Bacillus Anthraci., the 23S ribosomal RNA gene of Coxiella burnetii., the tRNA-fMet gene of Scytonema hofmanii, the tRNA-fMet gene of Synechocystis sp., the Thermotoga naphthophila. naphthophila.) 23S rRNA gene, Synechococcus elongatus ndhL and trnL-UAA gene or Thermotoga subterranea 23S rRNA gene or Phormidium sp. trnL gene introns have good self-splicing ability. Further, the self-splicing introns screened out were truncated at different sites to prepare 5' intron fragments and 3' intron fragments, and it was found that the intron fragments prepared by truncating at certain sites would bring higher RNA cyclization efficiency than the existing technology, such as Anabaena introns. Moreover, the inventors discovered that when an intron fragment prepared by truncation from a certain site of Bacillus anthracis is used, the precursor RNA will undergo cyclization while being transcribed in vitro, i.e., there is no need to arrange a cyclization step and a corresponding post-cyclization purification step after the in vitro transcription step, which greatly simplifies the process flow, reduces process residues, and also reduces, to a certain extent, the risk of reduced yield due to multi-step purification. Finally, the inventors optimized the homology arms in the circular RNA preparation vector based on the prior art such as the method disclosed by Daniel G.Anderson et al., so that the 5' homology arm and the 3' homology arm can complement each other when close to form a stem-loop structure, an inverted terminal repeat sequence (ITR) structure, or a similar structure, and the lengths of the 5' homology arm and the 3' homology arm are asymmetric. In this way, the intron fragments at both ends of the precursor RNA transcribed by the vector may be more tightly and stably combined together, thereby improving the efficiency of RNA cyclization. Specifically, in an exemplary embodiment, the inverted terminal repeat sequence (ITR) or a similar sequence contained in the adenovirus-related vector AAV is split into two in an asymmetric manner, and used as a 5' homology arm and a 3' homology arm, respectively. As shown in Figures 1A and 1B, when the 5' homology arm and the 3' homology arm in the transcription product are close, two palindromic arms and a long palindromic stem are formed. The presence of palindromic arms and / or the closed state of the end opposite to the palindromic stem (i.e., the junction of the two palindromic arms) may make the structure of the precursor RNA, especially the intron ribozyme therein, more stable, thereby improving the RNA cyclization efficiency and the circular RNA yield. Therefore, in the first aspect, the present application provides the use of an intron derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudomonas hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geophyta in preparing a vector for preparing circular RNA. The introns derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudoclase hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, and the 23S rRNA gene of Thermotoga geologica are all class I self-splicing introns, wherein the intron of the recA gene of Bacillus anthracis may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18; the intron of the 23S ribosomal RNA gene of Coxiella burnetii ... NO:19 or 59 having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Synechocystis tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:20; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:21; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:21 has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Pseudoclase hofmannii tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:60; the intron of the Synechococcus elongatus ndhL and trnL-UAA genes may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:61 has a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; or an intron of the Thermotoga geophila 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:62. Specifically, the present application provides a single-stranded DNA molecule, which comprises, from the 5' end to the 3' end, in sequence: a) a 3' self-splicing intron fragment comprising a 3' splicing site and b) a 5' self-splicing intron fragment comprising a 5' splicing site, wherein each element is operably linked, wherein the 3' self-splicing intron fragment comprising a 3' splicing site and the 5' self-splicing intron fragment comprising a 5' splicing site are derived from introns of the anthracis recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Pseudomonas hoffmannii tRNA-fMet gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geophyta 23S rRNA gene.The introns derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Pseudoclase hofmannii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the ndhL and trnL-UAA genes of Synechococcus elongatus, and the 23S rRNA gene of Thermotoga genomica are all class I self-splicing introns, wherein the intron of the recA gene of Bacillus anthracis may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18; the intron of the 23S ribosomal RNA gene of Coxiella burnetii ... NO:19 or 59 having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Synechocystis tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:20; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:21; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:21 has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Pseudoclase hofmannii tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:60; the intron of the Synechococcus elongatus ndhL and trnL-UAA genes may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:61 has a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; or an intron of the Thermotoga geophila 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:62. In some embodiments, the intron of the recA gene of Bacillus anthracis may comprise the nucleotide sequence as shown in SEQ ID NO:18; the intron of the 23S ribosomal RNA gene of Coxiella burnetii may comprise the nucleotide sequence as shown in SEQ ID NO:19 or 59; the intron of the tRNA-fMet gene of Pseudomonas hofmannii may comprise the nucleotide sequence as shown in SEQ ID NO:60; the intron of the tRNA-fMet gene of Synechocystis may comprise the nucleotide sequence as shown in SEQ ID NO:20; the intron of the 23S rRNA gene of Thermotoga naphthophilum may comprise the nucleotide sequence as shown in SEQ ID NO:21; the intron of the ndhL and trnL-UAA genes of Synechococcus elongatus may comprise the nucleotide sequence as shown in SEQ ID NO:61; or the intron of the 23S rRNA gene of Thermotoga geophyta may comprise the nucleotide sequence as shown in SEQ ID NO:62. In other embodiments, the introns of the recA gene of Bacillus anthracis may be as shown in SEQ ID NO:18; the introns of the 23S ribosomal RNA gene of Coxiella burnetii may be as shown in SEQ ID NO:19 or 59; the introns of the tRNA-fMet gene of Pseudomonas hofmannii may be as shown in SEQ ID NO:60; the introns of the tRNA-fMet gene of Synechocystis may be as shown in SEQ ID NO:20; the introns of the 23S rRNA gene of Thermotoga naphthophilum may be as shown in SEQ ID NO:21; the introns of the ndhL and trnL-UAA genes of Synechococcus elongatus may be as shown in SEQ ID NO:61; or the introns of the 23S rRNA gene of Thermotoga geophyta may be as shown in SEQ ID NO:62. The 3' self-splicing intron fragment can include a natural adjacent exon or a sequence corresponding to a natural adjacent exon at the 3' end. In some embodiments, the 3' self-splicing intron fragment can include a natural adjacent exon at the 3' end. The 5' self-splicing intron fragment can include a natural adjacent exon or a sequence corresponding to a natural adjacent exon at the 5' end. In some embodiments, the 5' self-splicing intron fragment can include a natural adjacent exon at the 5' end. The length of the exon can be about 3-200 nucleotides. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment may be derived from the same intron. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment may truncate SEQ ID NO:18 after nucleotide position 133, 195, or 294 of SEQ ID NO:18, truncate SEQ ID NO:19 after nucleotide position 100, 157, 206, or 245 of SEQ ID NO:19, truncate SEQ ID NO:20 after nucleotide position 112, 246, 298, 393, or 500 of SEQ ID NO:20, truncate SEQ ID NO:21 after nucleotide position 130, 314, 369, or 408 of SEQ ID NO:21, truncate SEQ ID NO:59 after nucleotide position 313 or 453 of SEQ ID NO:59, truncate SEQ ID NO:60 after nucleotide position 71, 140, 184, or 216 of SEQ ID NO:60 ... SEQ ID NO:61 is truncated after nucleotide position 135 or 186 of SEQ ID NO:61, or SEQ ID NO:62 is truncated after nucleotide position 94, 336, 492 or 577 of SEQ ID NO:62. In some embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment can respectively contain i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 77 and 78, xvii) SEQ ID NOs: NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 having nucleotide sequences with at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.In other embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment can respectively include i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 77 and 78, xvii) SEQ ID NOs: NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) the nucleotide sequence shown in SEQ ID NO:89 and 90. The 3' cleavage site and the 5' cleavage site can be dinucleotides, encoding, for example, AG and GU, or AC and AU, etc., respectively. The single-stranded DNA molecule of the present application may also contain a target gene between the 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site. In some embodiments, the target gene is a protein coding sequence or a non-coding sequence. The single-stranded DNA molecule of the present application further comprises a 5' homology arm at the 5' end of the 3' self-splicing intron fragment comprising the 3' splicing site, and a 3' homology arm at the 3' end of the 5' self-splicing intron fragment comprising the 5' splicing site. The sequences of the 5' homology arm and the 3' homology arm are complementary. In some embodiments, the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem; the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem; or the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem of two stem-loops, the stems of the two stem-loops are connected, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or the loop of one of the stem-loops. The lengths of the 5' homology arm and the 3' homology arm are different and can be in the range of 10-120 nucleotides. In some embodiments, the 5' homology arm and / or the 3' homology arm may comprise a sequence with CpG or a sequence without CpG. In some embodiments, the 5' homology arm and / or the 3' homology arm may comprise a sequence without CpG. The single-stranded DNA molecule of the present application may further comprise an internal ribosome entry site (IRES) coding sequence between the 3' self-splicing intron fragment comprising the 3' splicing site and the target gene. In some embodiments, the IRES can be selected from Coxsackievirus B3 (CVB3), Coxsackievirus A (CVB1 / 2), Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman poliovirus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus 1 type, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FG F2, human SFTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAP1, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, salivirus, coxsackievirus, double echovirus, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivelled disease virus, and IRES of the eIF4G aptamer. The single-stranded DNA molecule of the present application may further comprise a 3' spacer sequence between the target gene and the 5' self-splicing intron fragment comprising the 5' splicing site. In some embodiments, the length of the 5' spacer sequence and / or the 3' spacer sequence may be at least 10 nucleotides. The single-stranded DNA molecule of the present application may also contain an RNA polymerase promoter upstream of the 5' homology arm. In some embodiments, the RNA polymerase promoter is an RNA polymerase promoter derived from T7 virus, T6 virus, SP6 virus, T3 virus or T4 virus. In a second aspect, the present application provides DNA molecules and vectors that can be used to prepare circular RNA. Specifically, the present application provides a single-stranded DNA molecule for preparing circular RNA, which can sequentially comprise from the 5' end to the 3' end a) a 3' self-splicing intron fragment comprising a 3' splicing site, b) a target gene and c) a 5' self-splicing intron fragment comprising a 5' splicing site, wherein each element is operably linked, wherein the 3' self-splicing intron fragment comprising a 3' splicing site and the 5' self-splicing intron fragment comprising a 5' splicing site are derived from the intron of the anthracis recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Pseudoclase hofmannii tRNA-fMet gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geophyta 23S rRNA gene. The introns derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Pseudoclase hofmannii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the ndhL and trnL-UAA genes of Synechococcus elongatus, and the 23S rRNA gene of Thermotoga genomica are all class I self-splicing introns, wherein the intron of the recA gene of Bacillus anthracis may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18; the intron of the 23S ribosomal RNA gene of Coxiella burnetii ... NO:19 or 59 having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Synechocystis tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:20; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:21; the intron of the Naphthomyces 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:21 has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; the intron of the Pseudoclase hofmannii tRNA-fMet gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:60; the intron of the Synechococcus elongatus ndhL and trnL-UAA genes may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: NO:61 has a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity; or an intron of the Thermotoga geophila 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:62. In some embodiments, the intron of the recA gene of Bacillus anthracis may comprise the nucleotide sequence as shown in SEQ ID NO:18; the intron of the 23S ribosomal RNA gene of Coxiella burnetii may comprise the nucleotide sequence as shown in SEQ ID NO:19 or 59; the intron of the tRNA-fMet gene of Pseudomonas hofmannii may comprise the nucleotide sequence as shown in SEQ ID NO:60; the intron of the tRNA-fMet gene of Synechocystis may comprise the nucleotide sequence as shown in SEQ ID NO:20; the intron of the 23S rRNA gene of Thermotoga naphthophilum may comprise the nucleotide sequence as shown in SEQ ID NO:21; the intron of the ndhL and trnL-UAA genes of Synechococcus elongatus may comprise the nucleotide sequence as shown in SEQ ID NO:61; or the intron of the 23S rRNA gene of Thermotoga geophyta may comprise the nucleotide sequence as shown in SEQ ID NO:62. In other embodiments, the introns of the recA gene of Bacillus anthracis may be as shown in SEQ ID NO:18; the introns of the 23S ribosomal RNA gene of Coxiella burnetii may be as shown in SEQ ID NO:19 or 59; the introns of the tRNA-fMet gene of Pseudomonas hofmannii may be as shown in SEQ ID NO:60; the introns of the tRNA-fMet gene of Synechocystis may be as shown in SEQ ID NO:20; the introns of the 23S rRNA gene of Thermotoga naphthophilum may be as shown in SEQ ID NO:21; the introns of the ndhL and trnL-UAA genes of Synechococcus elongatus may be as shown in SEQ ID NO:61; or the introns of the 23S rRNA gene of Thermotoga geophyta may be as shown in SEQ ID NO:62. The 3' self-splicing intron fragment can include a natural adjacent exon or a sequence corresponding to a natural adjacent exon at the 3' end. In some embodiments, the 3' self-splicing intron fragment can include a natural adjacent exon at the 3' end. The 5' self-splicing intron fragment can include a natural adjacent exon or a sequence corresponding to a natural adjacent exon at the 5' end. In some embodiments, the 5' self-splicing intron fragment can include a natural adjacent exon at the 5' end. The length of the exon can be about 3-200 nucleotides. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment may be derived from the same intron. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment may truncate SEQ ID NO:18 after nucleotide position 133, 195, or 294 of SEQ ID NO:18, truncate SEQ ID NO:19 after nucleotide position 100, 157, 206, or 245 of SEQ ID NO:19, truncate SEQ ID NO:20 after nucleotide position 112, 246, 298, 393, or 500 of SEQ ID NO:20, truncate SEQ ID NO:21 after nucleotide position 130, 314, 369, or 408 of SEQ ID NO:21, truncate SEQ ID NO:59 after nucleotide position 313 or 453 of SEQ ID NO:59, truncate SEQ ID NO:60 after nucleotide position 71, 140, 184, or 216 of SEQ ID NO:60 ... SEQ ID NO:61 is truncated after nucleotide position 135 or 186 of SEQ ID NO:61, or SEQ ID NO:62 is truncated after nucleotide position 94, 336, 492 or 577 of SEQ ID NO:62. In some embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment can respectively contain i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 77 and 78, xvii) SEQ ID NOs: NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 having nucleotide sequences with at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.In other embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment can respectively include i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 77 and 78, xvii) SEQ ID NOs: NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) the nucleotide sequence shown in SEQ ID NO:89 and 90. The 3' cleavage site and the 5' cleavage site can be dinucleotides, encoding, for example, AG and GU, or AC and AU, etc., respectively. The "target gene" referred to in the context of applying for a single-stranded DNA molecule refers to a DNA sequence that can be transcribed into coding RNA or non-coding RNA. The target gene can be a protein coding sequence or a non-coding sequence. The length of the target gene can be 50-8000 nucleotides. The protein coding sequence can encode a protein of eukaryotic or prokaryotic origin. The protein coding sequence can encode a human protein or a non-human protein. In some embodiments, the protein coding sequence can encode an antigenic protein, an antibody, or a Cas9 endonuclease. In some embodiments, the protein coding sequence can encode a firefly luciferase or a Daphnia pulex luciferase. The single-stranded DNA molecule for preparing circular RNA of the present application may include a 5' homology arm at the 5' end of the 3' self-splicing intron fragment, and a 3' homology arm at the 3' end of the 5' self-splicing intron fragment. The sequences of the 5' homology arm and the 3' homology arm are complementary. In some embodiments, the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem; the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem; or the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem of two stem-loops, the stems of the two stem-loops are connected, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or the loop of one of the stem-loops. The lengths of the 5' homology arm and the 3' homology arm are different and can be in the range of 10-120 nucleotides. In one embodiment, the 5' homology arm may include the first sequence and the second sequence from the 5' end to the 3' end, and the 3' homology arm may include the third sequence, the fourth sequence, the fifth sequence and the sixth sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the second sequence is the reverse complementary sequence of the third sequence, and the fourth sequence is the reverse complementary sequence of the fifth sequence. The length of the first sequence, the fourth sequence, the fifth sequence and the sixth sequence may be 3-20 nucleotides. The length of the second sequence and the third sequence may be 20-50 nucleotides. In some embodiments, the length of the first sequence, the fourth sequence, the fifth sequence and the sixth sequence may be more than 3 nucleotides, more than 5 nucleotides, more than 10 nucleotides, or more than 15 nucleotides, and less than 20 nucleotides, less than 15 nucleotides, or less than 10 nucleotides. In some embodiments, the length of the second sequence and the third sequence may be more than 20 nucleotides, more than 25 nucleotides, more than 30 nucleotides, more than 35 nucleotides, more than 40 nucleotides, or more than 45 nucleotides. A seventh sequence may also be included between the fourth sequence and the fifth sequence, and the length of the seventh sequence may be 1-15 nucleotides, and the sequence may be non-complementary pairing within the sequence. The RNA sequence transcribed from the seventh sequence forms a loop portion in a hairpin (stem-loop) structure, or the inflection of a palindrome arm. In some embodiments, the length of the seventh sequence may be about 3 nucleotides, including, for example, 3 adenylic acids (A) or thymic acids (T). A connecting sequence having a length of 1-3 nucleotides may also be included between the fifth sequence and the sixth sequence. In some embodiments, the length of the connecting sequence may be 1 nucleotide. In one embodiment, the 5' homology arm comprises the first sequence, the second sequence, the third sequence and the fourth sequence from the 5' end to the 3' end, and the 3' homology arm comprises the fifth sequence and the sixth sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the fourth sequence is the reverse complementary sequence of the fifth sequence, and the second sequence is the reverse complementary sequence of the third sequence. The length of the first sequence, the second sequence, the third sequence and the sixth sequence may be 3-20 nucleotides. The length of the fourth sequence and the fifth sequence may be 20-50 nucleotides. In some embodiments, the length of the first sequence, the second sequence, the third sequence and the sixth sequence may be more than 3 nucleotides, more than 5 nucleotides, more than 10 nucleotides, or more than 15 nucleotides, and less than 20 nucleotides, less than 15 nucleotides, or less than 10 nucleotides. In some embodiments, the length of the 4th sequence and the 5th sequence can be more than 20 nucleotides, more than 25 nucleotides, more than 30 nucleotides, more than 35 nucleotides, more than 40 nucleotides, or more than 45 nucleotides. A 7th sequence can also be included between the 2nd sequence and the 3rd sequence, and the length of the 7th sequence can be 1-15 nucleotides, and the sequence is not complementary inside. The RNA transcribed from the 7th sequence forms a loop in a hairpin (stem-loop) structure, or the inflection of a palindrome arm. In some embodiments, the length of the 7th sequence can be about 3 nucleotides, including, for example, 3 adenylic acids (A) or thymic acids (T). A connecting sequence with a length of 1-3 nucleotides can also be included between the 1st sequence and the 2nd sequence. In some embodiments, the length of the connecting sequence can be 1 nucleotide. The 5' homology arm and / or the 3' homology arm may comprise a sequence with CpG or a sequence without CpG. In some embodiments, the 5' homology arm and / or the 3' homology arm may comprise a sequence without CpG. In some embodiments, the 5' homology arm and the 3' homology arm can respectively comprise nucleotide sequences having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to i) SEQ ID NOs: 13 and 14; or ii) SEQ ID NOs: 15 and 16. The single-stranded DNA molecule for preparing circular RNA of the present application may also contain an IRES coding sequence between the 3' self-splicing intron fragment and the target gene. IRES may be selected from Coxsackievirus B3 (CVB3), Coxsackievirus A (CVB1 / 2), Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, fire ant virus 1, aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glaucous leafhopper virus-1, human immunodeficiency virus type 1, glaucous leafhopper virus- 1. Lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human S FTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAP1, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, salivirus, coxsackievirus, double echovirus, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivelled disease virus, or an IRES of the eIF4G aptamer. In some embodiments, the IRES may be an IRES of Coxsackievirus B3 (CVB3), the coding sequence of which may comprise a nucleotide sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5. In some embodiments, the IRES coding sequence may be as shown in SEQ ID NO: 5. The single-stranded DNA molecule for preparing circular RNA of the present application can also include a 5' spacer sequence between the 3' self-splicing intron fragment and the IRES coding sequence and / or a 3' spacer sequence between the target gene and the 5' self-splicing intron fragment. The length of the 5' spacer sequence and / or the 3' spacer sequence can be 5-70 nucleotides, for example, at least 10 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, or at least 60 nucleotides. In some embodiments, the 5' spacer sequence and / or the 3' spacer sequence are polyA, polyC or polyA-C. In some embodiments, the 5' spacer sequence and the 3' spacer sequence respectively include the nucleotide sequences shown in SEQ ID NO:4 and 9. The single-stranded DNA molecule for preparing circular RNA of the present application may also include an RNA polymerase promoter at the 5' end, such as the upstream of the 3' self-splicing intron fragment or the 5' homology arm. The RNA polymerase promoter may be an RNA polymerase promoter derived from T7 virus, T6 virus, SP6 virus, T3 virus, or T4 virus. In some embodiments, the RNA polymerase promoter may be a T7 virus promoter, which may include a nucleotide sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 1. In some embodiments, the RNA polymerase promoter may be as shown in SEQ ID NO: 1. The single-stranded DNA molecule used to prepare circular RNA of the present application may also contain a restriction endonuclease site at the 3' end, such as downstream of the 5' self-splicing intron fragment or the 3' homology arm. The restriction endonuclease site may be, for example, EcoRI or EcoRV. In some embodiments, the single-stranded DNA molecule for preparing circular RNA of the present application may contain a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an internal ribosome entry site (IRES) coding sequence, e) a protein coding sequence, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment containing a 5' splicing site, and h) a 3' homology arm; or a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an internal ribosome entry site (IRES), e) a protein coding sequence, f) a 5' self-splicing intron fragment containing a 5' splicing site, and g) a 3' homology arm. In some embodiments, the single-stranded DNA molecule for preparing circular RNA of the present application may include a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' cleavage site, c) a non-coding sequence, d) a 5' self-splicing intron fragment containing a 5' cleavage site, and e) a 3' homology arm. The present application also provides a single-stranded DNA molecule for preparing circular RNA, which can sequentially comprise from the 5' end to the 3' end a) a 5' homology arm, b) a 3' self-splicing intron fragment comprising a 3' splicing site, c) a target gene, d) a 5' self-splicing intron fragment comprising a 5' splicing site, and e) a 3' homology arm, wherein each element is operably connected, wherein the sequences of the 5' homology arm and the 3' homology arm can i) complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' homology arm are The 3' ends are adjacent in the stem portion; ii) complementation forms a structure comprising a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, and wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem portion; or iii) complementation forms a structure comprising a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of two stem-loops, the stem portions of the two stem-loops are connected, and wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or the loop portion of one of the stem-loops. The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site can be derived from any self-splicing intron, including class I and class II, particularly class I self-splicing introns. In some embodiments, the 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site can be derived from the anthracis recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Pseudoclase hofmannii tRNA-fMet gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geophyta 23S rRNA gene. The single-stranded DNA molecule may also optionally comprise a 5' spacer sequence, an IRES coding sequence and a 3' spacer sequence. Other aspects of the definitions of the target gene, 5' spacer sequence, IRES coding sequence, 3' spacer sequence, 5' homology arm and 3' homology arm, and the 3' self-splicing intron fragment and the 5' self-splicing intron fragment derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudomonas hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geogensis in the single-stranded DNA molecule are the same as the definitions of the elements in the single-stranded DNA molecule mentioned above. The present application also provides a double-stranded DNA molecule, which may include i) a single-stranded DNA molecule of the present application, and ii) a second strand substantially complementary to the single-stranded DNA molecule. In some embodiments, the double-stranded DNA molecule of the present application may include i) a single-stranded DNA molecule of the present application, and ii) a second strand fully complementary to the single-stranded DNA molecule. In some embodiments, the double-stranded DNA molecule is a double-stranded DNA molecule for preparing circular RNA. The present application also provides a vector comprising the single-stranded DNA molecule or double-stranded DNA molecule of the present application. In some embodiments, the vector may be a vector for preparing circular RNA, comprising the single-stranded DNA molecule for preparing circular RNA of the present application, or the double-stranded DNA molecule for preparing circular RNA. The carrier can be circular or linear. In some embodiments, the carrier can be linear. In some embodiments, the carrier can be circular and processed to become linear. The vector of the present application can transcribe the circular RNA of about 500 to about 10000 nucleotides. In some embodiments, the vector of the present application can transcribe the circular RNA of at least 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 nucleotides. In a third aspect, the present application provides a method for preparing a circular RNA molecule, comprising i) in vitro transcribing a precursor RNA from a vector for preparing a circular RNA of the present application under suitable conditions, and ii) incubating the precursor RNA under suitable conditions, wherein the suitable conditions of step ii) include the presence of magnesium ions and guanosine triphosphate (GTP). The concentration of GTP may be 2 mM; the concentration of magnesium ions may be 10 mM-20 mM. In some embodiments, suitable conditions for step i) include incubation at about 37°C for about 2 hours in the presence of nucleoside triphosphates. In some embodiments, suitable conditions for step i) include incubation at about 37°C for about 2 hours in the presence of nucleoside triphosphates, and addition of DNase I, incubation at about 37°C for about 30 minutes. In some embodiments, suitable conditions for step ii) include incubation at about 70°C for 5 minutes, placing on ice for 3 minutes, adding GTP and Mg 2+ , incubate at about 55°C for 8 minutes. The present application also provides a method for preparing a circular RNA molecule, comprising subjecting the vector for preparing circular RNA of the present application to in vitro transcription under suitable conditions, wherein the 3' self-splicing intron fragment and the 5' self-splicing intron fragment in the vector respectively comprise nucleotide sequences having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NOs: 41 and 42 or SEQ ID NOs: 43 and 44, wherein the suitable conditions include the presence of magnesium ions and nucleoside triphosphates. In some embodiments, the suitable conditions include, in the presence of nucleoside triphosphates and Mg ions, 2+ Incubate at about 37°C for about 2 hours in the presence of Mg. In some embodiments, suitable conditions include incubating at about 37°C for about 2 hours in the presence of Mg. 2+ and incubating at about 37° C. for about 2 hours in the presence of , and adding DNase I, and incubating at about 37° C. for about 30 minutes. In some embodiments, the nucleoside triphosphate is guanosine triphosphate. In a fourth aspect, the present application provides a circularizable RNA molecule, which comprises, from the 5' end to the 3' end, in sequence: a) an optional 5' homology arm, b) a 3' self-splicing intron fragment comprising a 3' splicing site, c) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment comprising a 5' splicing site, and h) an optional 3' homology arm; or a) an optional 5' homology arm, b) a 3' self-splicing intron fragment comprising a 3' splicing site, c) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment comprising a 5' splicing site, and h) an optional 3' homology arm. ) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 5' self-splicing intron fragment containing a 5' splicing site, and g) an optional 3' homology arm, wherein the target gene is a protein coding sequence, and each element is operably linked, wherein the 3' self-splicing intron fragment containing a 3' splicing site and the 5' self-splicing intron fragment containing a 5' splicing site are derived from the recA gene of Bacillus anthracis, the 23S ribosomal gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the intron of the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudomonas hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geophyta. The present application also provides a circularizable RNA molecule, which comprises, from the 5' end to the 3' end, in sequence: a) an optional 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a target gene, d) a 5' self-splicing intron fragment containing a 5' splicing site, and e) an optional 3' homology arm, wherein the target gene is a non-coding sequence, and each element is operably connected, wherein the 3' self-splicing intron fragment containing a 3' splicing site and the 5' self-splicing intron fragment containing a 5' splicing site are derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis sp., the intron of the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudomonas hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geophyta. The intron of the Bacillus anthracis recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Coxiella burnetii 23S ribosomal RNA gene-2, the Pseudoclase hofmannii tRNA-fMet gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geogensis 23S rRNA gene may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 18-21 and SEQ ID NOs: 59-62, respectively. In some embodiments, the intron of the Bacillus anthracis recA gene, the Pseudoclase hofmannii tRNA-fMet gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geophila 23S rRNA gene may comprise the nucleotide sequence as shown in SEQ ID NO: 18, 60, 20, 21, 61 or 62, respectively; the intron of the Coxiella burnetii 23S ribosomal RNA gene may comprise the nucleotide sequence as shown in SEQ ID NO: 19 or 59. The 3' self-splicing intron fragment may contain an RNA sequence corresponding to a natural adjacent exon at the 3' end. The 5' self-splicing intron fragment may contain an RNA sequence corresponding to a natural adjacent exon at the 5' end. The length of the exon may be about 3-200 nucleotides. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment may be derived from the same intron. The 3' self-splicing intron fragment and the 5' self-splicing intron fragment can be respectively composed of i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 77 and 78, xvii) SEQ ID NOs: 79 and 80, xviii) SEQ ID NOs: NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity,i.e. comprising i) SEQ ID NOs:41 and 42, ii) SEQ ID NOs:43 and 44, iii) SEQ ID NOs:47 and 48, iv) SEQ ID NOs:75 and 76, v) SEQ ID NOs:39 and 40, vi) SEQ ID NOs:49 and 50, vii) SEQ ID NOs:51 and 52, viii) SEQ ID NOs:53 and 54, ix) SEQ ID NOs:55 and 56, x) SEQ ID NOs:57 and 58, xi) SEQ ID NOs:67 and 68, xii) SEQ ID NOs:69 and 70, xiii) SEQ ID NOs:71 and 72, xiv) SEQ ID NOs:73 and 74, xv) SEQ ID NOs:45 and 46, xvi) SEQ ID NOs:77 and 78, xvii) SEQ ID NOs:79 and 80, xviii) SEQ ID NOs:81 and 82, xix) SEQ ID NOs:83 and 84 NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 having a corresponding RNA sequence of a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. , The 3' cleavage site and the 5' cleavage site may be dinucleotides, such as AG and GU, or AC and AU, respectively. The sequences of the 5' homology arm and the 3' homology arm may be substantially complementary or completely complementary. In some embodiments, the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem; the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem; or the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem of two stem-loops, the stems of the two stem-loops are connected, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or the loop of one of the stem-loops. The lengths of the 5' homology arm and the 3' homology arm are different and can be in the range of 10-120 nucleotides. In one embodiment, the 5' homology arm may include the first sequence and the second sequence from the 5' end to the 3' end, and the 3' homology arm may include the third sequence, the fourth sequence, the fifth sequence and the sixth sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the second sequence is the reverse complementary sequence of the third sequence, and the fourth sequence is the reverse complementary sequence of the fifth sequence. The length of the first sequence, the fourth sequence, the fifth sequence and the sixth sequence may be 3-20 nucleotides. The length of the second sequence and the third sequence may be 20-50 nucleotides. In some embodiments, the length of the first sequence, the fourth sequence, the fifth sequence and the sixth sequence may be more than 3 nucleotides, more than 5 nucleotides, more than 10 nucleotides, or more than 15 nucleotides, and less than 20 nucleotides, less than 15 nucleotides, or less than 10 nucleotides. In some embodiments, the length of the second sequence and the third sequence may be more than 20 nucleotides, more than 25 nucleotides, more than 30 nucleotides, more than 35 nucleotides, more than 40 nucleotides, or more than 45 nucleotides. A seventh sequence may also be included between the fourth sequence and the fifth sequence, and the length of the seventh sequence may be 1-15 nucleotides, and the sequence may be non-complementary pairing within the sequence. The RNA sequence transcribed from the seventh sequence forms a loop portion in a hairpin (stem-loop) structure, or the inflection of a palindrome arm. In some embodiments, the length of the seventh sequence may be about 3 nucleotides, including, for example, 3 adenylic acids (A) or thymic acids (T). A connecting sequence having a length of 1-3 nucleotides may also be included between the fifth sequence and the sixth sequence. In some embodiments, the length of the connecting sequence may be 1 nucleotide. In one embodiment, the 5' homology arm comprises the first sequence, the second sequence, the third sequence and the fourth sequence from the 5' end to the 3' end, and the 3' homology arm comprises the fifth sequence and the sixth sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the fourth sequence is the reverse complementary sequence of the fifth sequence, and the second sequence is the reverse complementary sequence of the third sequence. The length of the first sequence, the second sequence, the third sequence and the sixth sequence may be 3-20 nucleotides. The length of the fourth sequence and the fifth sequence may be 20-50 nucleotides. In some embodiments, the length of the first sequence, the second sequence, the third sequence and the sixth sequence may be more than 3 nucleotides, more than 5 nucleotides, more than 10 nucleotides, or more than 15 nucleotides, and less than 20 nucleotides, less than 15 nucleotides, or less than 10 nucleotides. In some embodiments, the length of the 4th sequence and the 5th sequence can be more than 20 nucleotides, more than 25 nucleotides, more than 30 nucleotides, more than 35 nucleotides, more than 40 nucleotides, or more than 45 nucleotides. A 7th sequence can also be included between the 2nd sequence and the 3rd sequence, and the length of the 7th sequence can be 1-15 nucleotides, and the sequence is not complementary inside. The RNA transcribed from the 7th sequence forms a loop in a hairpin (stem-loop) structure, or the inflection of a palindrome arm. In some embodiments, the length of the 7th sequence can be about 3 nucleotides, including, for example, 3 adenylic acids (A) or thymic acids (T). A connecting sequence with a length of 1-3 nucleotides can also be included between the 1st sequence and the 2nd sequence. In some embodiments, the length of the connecting sequence can be 1 nucleotide. The 5' homology arm and / or the 3' homology arm may comprise a sequence with CpG or a sequence without CpG. In some embodiments, the 5' homology arm and / or the 3' homology arm may comprise a sequence without CpG. The length of the 5' spacer sequence and / or the 3' spacer sequence can be 5-70 nucleotides, for example, at least 10 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, or at least 60 nucleotides. In some embodiments, the 5' spacer sequence and / or the 3' spacer sequence is polyA, polyC or polyA-C. In some embodiments, the 5' spacer sequence and the 3' spacer sequence can be transcribed from SEQ ID NO: 4 and 9, respectively, i.e., contain the corresponding RNA sequences of SEQ ID NO: 4 and 9. The internal ribosome entry site (IRES) can be coxsackievirus B3 (CVB3), coxsackievirus A (CVB1 / 2), Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, red fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus type 1, Green leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2 , human SFTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, salivirus, coxsackievirus, double echovirus, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivell disease virus, or an IRES for the eIF4G aptamer. In some embodiments, the IRES may be the IRES of Coxsackievirus B3 (CVB3), which is transcribed from the nucleotide sequence shown in SEQ ID NO:5, ie, contains the corresponding RNA sequence of SEQ ID NO:5. The "target gene" referred to in the context of the circularizable RNA molecule of the present application refers to coding RNA or non-coding RNA, wherein the coding RNA can be further translated into protein. The target gene can be a protein coding sequence or a non-coding sequence. The length of the target gene can be 50-8000 nucleotides. The protein coding sequence can encode a protein of eukaryotic or prokaryotic origin. The protein coding sequence can encode a human protein or a non-human protein. In some embodiments, the protein coding sequence can encode an antigenic protein, an antibody, or a Cas9 endonuclease. In some embodiments, the protein coding sequence can encode a firefly luciferase or a long-bellied water flea luciferase. In some embodiments, the circularizable RNA molecule of the present application can be obtained by transcription (in vitro transcription or intracellular transcription) using the vector of the present application. The present application also provides a circularizable RNA molecule, which comprises, from the 5' end to the 3' end, in sequence: a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment containing a 5' splicing site, and h) a 3' homology arm, wherein the target gene is a protein coding sequence; or a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 5' self-splicing intron fragment containing a 5' splicing site, and g) a 3' homology arm, wherein the target gene is a protein coding sequence; or a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an IRES, e) a target gene, f) a 5' self-splicing intron fragment containing a 5' splicing site, and g) a 3' homology arm, wherein the target gene is a protein coding sequence; The invention relates to a method for preparing an intracellular protein sequence comprising: a 5' self-splicing intron fragment and e) a 3' homology arm of the invention, wherein the target gene is a non-coding sequence, wherein each element is operably connected, wherein the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem portion; the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem portion; or the sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of two stem-loops, the stem portions of the two stem-loops are connected, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or in the loop portion of one of the stem-loops. The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site can be derived from any self-splicing intron, including class I and class II, particularly class I self-splicing introns. In some embodiments, the 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site can be derived from the anthracis recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Pseudoclase hofmannii tRNA-fMet gene, the Synechococcus elongatus ndhL and trnL-UAA genes, or the Thermotoga geophyta 23S rRNA gene. Other aspects of the definitions of the 5' homology arm, 5' spacer sequence, internal ribosome entry site (IRES), target gene, 3' spacer sequence, 3' homology arm, and the 3' self-splicing intron fragment and the 5' self-splicing intron fragment derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudomonas hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geophyta in the circularizable RNA molecule are the same as the definitions of the elements in the circularizable RNA molecule mentioned above. In a fifth aspect, the present application provides a circular RNA molecule, which can be obtained by the method for preparing circular RNA of the present application using the vector for preparing circular RNA of the present application. The present application also provides a circular RNA, which can be obtained by treating the circularizable RNA molecule of the present application under suitable conditions. Suitable conditions refer to the presence of magnesium ions and guanosine triphosphate (GTP). In some embodiments, suitable conditions include, in the presence of guanosine triphosphate and Mg 2+ Incubate at about 37°C for about 2 hours in the presence of GTP and Mg. 2+ In the presence of , incubate at about 37°C for about 2 hours, and add DNase I, incubate at about 37°C for about 30 minutes. The concentration of GTP may be 2 mM; the concentration of magnesium ions may be 10 mM-20 mM. Circular RNA molecules can be translated into proteins in cells or exist as biologically active non-coding RNAs. The length of the circular RNA can be at least 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 nucleotides. In a sixth aspect, the present application provides a host cell, which may contain the single-stranded DNA molecule, double-stranded DNA molecule, vector, circularizable RNA molecule or circular RNA molecule of the present application. The application also provides a composition, which may include a single-stranded DNA molecule, a double-stranded DNA molecule, a vector, a circularized RNA molecule, or a host cell of the application. The composition can be used to prepare circularized RNA and / or circular RNA, particularly to produce a translatable protein or a biologically active circular RNA in vitro or in vivo. The biologically active circular RNA may be, for example, a miRNA sponge or a non-coding RNA. The composition of the application (including a single-stranded DNA molecule, a double-stranded DNA molecule) can be used to prepare a circular RNA preparation vector. The present application also provides a composition, which may include the circular RNA molecule of the present application. The composition may be a pharmaceutical composition, and may also include a pharmaceutically acceptable carrier. The composition may be transfected into cells, for example, by liposome transfection, electroporation, or nanocarrier encapsulation. The present application also provides the use of the composition for preparing circular RNA, or for in vivo treatment, etc. For example, in one embodiment, the present application provides a method for expressing a vaccine, a therapeutic protein, or other types of proteins in a subject in need thereof, comprising administering the composition comprising circular RNA of the present application to the subject. The therapeutic protein may be, for example, an antibody, a fusion protein, etc. In the seventh aspect, the present application provides a method for screening introns with self-splicing ability, comprising: i) providing a double-stranded DNA molecule, which comprises a promoter, a first sequence, a 5' natural adjacent exon of the intron to be screened or a sequence corresponding to the natural adjacent exon, the intron to be screened, the 3' natural adjacent exon of the intron to be screened or a sequence corresponding to the natural adjacent exon, and a second sequence from the 5' end to the 3' end; ii) transcribing the double-stranded DNA molecule of step i) to obtain an RNA molecule; iii) treating the RNA molecule of step ii) under suitable conditions, wherein the suitable conditions include the presence of magnesium ions and guanosine triphosphate (GTP); and iv) analyzing whether the RNA molecule treated by step iii) contains the transcription product sequence of the intron to be screened, wherein the absence of the transcription product sequence of the intron to be screened in the RNA molecule treated by step iii) indicates that the intron to be screened is an intron with self-splicing ability. The first sequence and the second sequence may be any sequence. The promoter may be a T7 promoter. The transcription in step ii) can be performed by in vitro transcription. The analysis of step iv) may include reverse transcribing the RNA molecule treated in step iii) into a single-stranded DNA molecule, and sequencing the single-stranded DNA molecule or sequencing the RNA molecule treated in step iii), wherein the absence of the sequence of the intron to be screened indicates that the intron to be screened is an intron with self-splicing ability. If the intron structure is determined, but it is uncertain whether the intron has the ability to self-splicing, the intron sequence to be screened may be analyzed to determine whether it is missing according to step iv). The analysis of step iv) may include reverse transcribing the RNA molecule treated in step iii) into a single-stranded DNA molecule, converting the single-stranded DNA molecule into a double-stranded DNA molecule, and comparing the length of the double-stranded DNA molecule with that of the double-stranded DNA molecule in step i), wherein the length of the double-stranded DNA molecule is shorter than that of the double-stranded DNA molecule in step i), indicating that the intron to be screened is an intron with self-splicing ability. The analysis of step iv) may include comparing the length of the RNA molecule of step ii) with the length of the RNA molecule treated in step iii). The comparison of the length of the RNA molecule of step ii) with the length of the RNA molecule treated in step iii) may be performed by gel electrophoresis. Specifically, the analysis of step iv) may include comparing the moving speed of the RNA molecule of step ii) with the moving speed of the RNA molecule treated in step iii) in gel electrophoresis, wherein the moving speed of the RNA molecule treated in step iii) is greater than that of the RNA molecule in step ii), indicating that the intron to be screened is an intron with self-splicing ability. The gel in the gel electrophoresis may contain 1% agarose, and the gel electrophoresis may be performed for 20 minutes. The analysis of step iv) may also include, after gel electrophoresis, recovering the RNA molecule treated in step iii) from the gel, reversely transcribing the RNA molecule into a single-stranded DNA molecule, converting the single-stranded DNA molecule into a double-stranded DNA molecule, and comparing the length of the double-stranded DNA molecule with the length of the double-stranded DNA molecule in step i), wherein the length of the double-stranded DNA molecule is less than that of the double-stranded DNA molecule in step i), indicating that the intron to be screened is an intron with self-splicing ability. Comparison of the length of the double-stranded DNA molecule with the length of the double-stranded DNA molecule in step i) can be performed by gel electrophoresis. Alternatively, the analysis in step iv) can also include, after gel electrophoresis, recovering the RNA molecule treated in step iii) from the gel, reverse transcribing the RNA molecule into a single-stranded DNA molecule, and sequencing the single-stranded DNA molecule, wherein the absence of the sequence of the intron to be screened indicates that the intron to be screened is an intron with self-splicing ability. Based on the following detailed description and examples, other features and advantages of the current disclosure will be very clear, and the detailed description and examples should not be interpreted as limiting. All documents, Genbank registration numbers, patents and published patent applications cited in the specification are incorporated herein by reference. BRIEF DESCRIPTION OF THE DRAWINGS The following detailed description is given by way of example but is not intended to limit the present invention to the specific embodiments described and can be better understood in conjunction with the accompanying drawings. Figures 1A-1D show the design principle of the 5' homology arm and the 3' homology arm in the vector constructed in the present application (1A), the basic structural schematic diagram of the vector transcription product (1B), the gel electrophoresis diagram (1C) and the capillary electrophoresis diagram (1D) of the vector in vitro transcription (IVT) product and the circular RNA formed by its circularization. Figures 2A-2C show the schematic diagram of the construction of the intron screening vector (2A) and the E-Gel transcription product after intron splicing. TM EX gel image (2B), agarose gel electrophoresis image of the vector transcription product after intron splicing (2C). [Corrected 26.07.2024 according to Rule 26] Figures 3A-3L show the results of capillary gel electrophoresis of the following sequences: Anabaena intron (3A), Synechocystis tRNA-fMet intron (P3 truncation, 3B), Coxiella burnetii 23S ribosomal RNA intron (P4 truncation, 3C), Thermotoga naphthophilum 23S The purity of circular RNA obtained in the transcription circularization step of vectors containing rRNA intron (P1 truncated, 3D), Bacillus anthracis recA intron (P2 truncated, 3E), Bacillus anthracis recA intron (P3 truncated, 3F), Coxiella burnetii 23S ribosomal RNA gene intron (P1 truncated, 3G), Coxiella burnetii 23S ribosomal RNA gene intron (P2 truncated, 3H), Pseudomonas hoffmannii tRNA-fMet gene intron (P3 truncated, 3I), Synechococcus elongatus ndhL and trnL-UAA gene intron (P1 truncated, 3J), Thermotoga geophila 23S rRNA gene intron (P2 truncated, 3K) and Thermotoga geophila 23S rRNA gene intron (P3 truncated, 3L). 4A and 4B show the purity of circular RNA obtained in the co-transcriptional circularization step of vectors containing the Anabaena intron (4A) and the Bacillus anthracis recA intron (P3 truncation, 4B) detected by capillary gel electrophoresis. DETAILED DESCRIPTION The present application relates to a vector for preparing circular RNA, which comprises: a) an optional 5' homology arm, b) a 3' self-splicing intron fragment comprising a 3' splicing site, c) an optional 5' spacer sequence, d) an optional internal ribosome entry site (IRES) coding sequence, e) a target gene, f) an optional 3' spacer sequence, g) a 5' self-splicing intron fragment comprising a 5' splicing site and h) an optional 3' homology arm, wherein each element is operably linked in sequence. The term "vector" refers to a naturally occurring or synthetic DNA fragment, including single-stranded and double-stranded DNA fragments, such as chemically synthesized DNA fragments, natural plasmids, or modified viral genomes. Exogenous DNA fragments can be inserted into the vector to clone and / or express the exogenous DNA fragment. The vector may contain, for example, an origin of replication, a selective marker or reporter gene, a multiple cloning site (MCS), etc. The term includes linear DNA fragments (such as PCR products, linearized plasmid fragments, etc.), plasmid vectors, viral vectors, bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), etc. When the vector is double-stranded DNA, the description of the order of elements and the direction of the element sequence is for one of the DNA chains. In a double-stranded vector, the two DNA chains are substantially complementary or completely complementary, that is, at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing is formed between the two DNA chains. "Complementarity" or "base pairing" refers to the connection of the bases in two DNA chains by hydrogen bonds and the like according to the corresponding relationship of AT and CG. The elements in the vector are "operably linked" in the sense that the elements can be transcribed in vitro or in vivo to form a precursor RNA product. “Precursor RNA”, “IVT transcription product”, “messenger RNA”, “mRNA” or “circularizable RNA” refers to the RNA product transcribed from the vector of the present application, which can be circularized under appropriate conditions to form circular RNA. "In vitro transcription" or "IVT" refers to the process of forming RNA in an in vitro cell-free system using DNA as a template in the presence of RNA transcriptase, NTPs, etc., to simulate the in vivo transcription process. When a plasmid vector is used as a DNA template, the plasmid line is cut with enzymes using restriction sites to linearize it before in vitro transcription. Exons refer to sequences in DNA that appear on mature RNA molecules. Exons are separated by introns and are connected together after being processed to remove introns after transcription. In contrast, introns are sequences that separate exons, which are transcribed in precursor RNAs, removed by splicing, and ultimately do not appear in mature RNA molecules. The removal of introns usually requires the participation of spliceosomes, which are ribonucleoprotein complexes that are dynamically composed of small nuclear RNAs (snRNAs, U1, U2, U4, U5, U6, etc.) and protein factors (about 100 kinds), recognize the splicing sites of RNA precursors, and catalyze splicing reactions. However, a very small number of introns that form ribozymes will undergo self-splicing, and the function of splicing enzymes in the form of RNA alone will be performed. The term "self-splicing intron" as used herein refers to an intron that can undergo splicing by itself without the need for a spliceosome. The conditions for splicing of a self-splicing intron include the presence of GTP and magnesium ions. In some embodiments, the conditions for splicing of a self-splicing intron include incubating at about 70°C for 5 minutes, placing on ice for 3 minutes, adding GTP and Mg ions, and then heating the intron to a temperature of 70°C for 5 minutes. 2+ , incubate at about 55°C for 8 minutes. According to the structure and splicing mechanism, self-splicing introns are generally divided into two categories, namely class I and class II. The self-splicing introns in this application mainly refer to class I introns. The inventors screened introns from various organisms and found that introns from Bacillus anthracis, Coxiella burnetii, Synechocystis, Thermotoga naphthophilum, Pseudoclase Hofmannii, Synechococcus elongatus, or Thermotoga geodesiccus, specifically introns from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the 23S rRNA gene of Thermotoga naphthophilum, the tRNA-fMet gene of Pseudoclase Hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the 23S rRNA gene of Thermotoga geodesiccus, have good self-splicing ability. These introns are all class I self-splicing introns. Self-splicing of introns usually requires the assistance of exons at both ends. Therefore, when preparing the vector of the present application, partial exon sequences on both sides of the introns are usually used. Specifically, the above-mentioned introns are truncated at different sites, the 3' end intron fragment and the exon fragment are placed on the 5' side of the vector (relative to a main chain DNA of the vector), and the 5' end exon fragment and the intron fragment are placed on the 3' side of the vector, and the target gene is placed between the two. The sequence of the exon is preferably naturally present on the side of the intron. The 3' intron fragment needs to contain a 3' splicing site, and the 5' intron fragment needs to contain a 5' splicing site. The 3' splicing site and the 5' splicing site can be dinucleotides, encoding, for example, AG and GU, or AC and AU, etc., respectively. The 3' intron fragment may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 3' end fragment of a natural intron. In particular, the 3' intron fragment may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 3' end fragment of a natural intron and the 3' exon fragment. The 5' intron fragment may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 5' end fragment of a natural intron. In particular, the 5' intron fragment may comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 5' end fragment of a natural intron and the 5' exon fragment. "Sequence identity" herein refers to the percentage of nucleotides / amino acids in a sequence that are identical to the nucleotides / amino acid residues in a reference sequence after sequence alignment, and if necessary, spaces are introduced in the sequence comparison to achieve the maximum percentage of sequence identity between the two sequences. Those skilled in the art can perform pairwise sequence comparisons or multiple sequence alignments to determine the percentage of sequence identity between two or more nucleic acid or amino acid sequences by a variety of methods, such as using computer software, such as ClustalOmega, T-coffee, Kalign, and MAFFT, etc. The self-splicing introns screened out were truncated at different sites to prepare 5' intron fragments and 3' intron fragments. It was found that the intron fragments prepared by truncating at certain sites would bring higher RNA cyclization efficiency than the prior art, such as the intron of Anabaena. Even more, when the P3 cutoff point of the anthrax Bacillus recA gene was selected, only in vitro transcription conditions were required to complete transcription and cyclization at the same time, which was very unexpected. For the truncation site of the intron, the inventors of the present application predicted the folding configuration of the intron transcribed RNA through RNA folding software such as RNAFold, selected a suitable stem-loop (hairpin) structure in the sequence located in the middle, and truncated at the loop. "Homology arm" refers to i) an RNA sequence that can form at least about 25%, 50%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing with another RNA (e.g., another homology arm); ii) a DNA sequence that encodes an RNA sequence that can form at least about 25%, 50%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing with an RNA sequence encoded by another DNA sequence (e.g., another homology arm). The "homology arm" in the circularizable RNA in the present application refers to the above-mentioned case i), and the "homology arm" in the vector of the present application refers to the above-mentioned case ii). In certain embodiments, the 5' homology arm and the 3' homology arm in the vector of the present application can respectively transcribe a segment of RNA, and these two segments of RNA (corresponding to the 5' homology arm and the 3' homology arm in the circularizable RNA molecule) can, when approaching each other, i) complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm transcription product and the 3' end of the 3' homology arm transcription product are adjacent in the stem portion; ii) complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, wherein the 5' end of the 5' homology arm transcription product and the 3' end of the 3' homology arm transcription product are adjacent in the palindromic stem portion; or iii) complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of two stem-loops, the stem portions of the two stem-loops are connected, wherein the 5' end of the 5' homology arm transcription product and the 3' end of the 3' homology arm transcription product are adjacent in the palindromic stem or the loop portion of one of the stem-loops. Due to the existence of the palindrome structure and the selection of the junction position of the two arms, the structure of the intron ribozyme can be made to exist more stably, thereby improving the RNA cyclization efficiency and the circular RNA yield. "Circular RNA" or "circRNA" is a type of RNA formed by covalent bonding (reverse splicing) of the 5' end and 3' end of linear RNA, which can be naturally occurring or artificially prepared. Some circular RNAs can encode proteins, while others are non-coding RNAs. Circular RNAs are not cut by exonucleases because they do not have 5' or 3' ends, and are more stable than linear RNAs. The fracture form of circular RNA molecules caused by hydrolysis and other reasons is referred to as "open-ring (nicked) RNA" in this article. When the vector of the present application is used to prepare circular RNA, the proportion of open-ring RNA is greatly reduced. In one embodiment, the 5' homology arm may include the first sequence and the second sequence in sequence from the 5' end to the 3' end, and the 3' homology arm may include the third sequence, the fourth sequence, the fifth sequence, and the sixth sequence in sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the second sequence is the reverse complementary sequence of the third sequence, and the fourth sequence is the reverse complementary sequence of the fifth sequence (Figure 1B, top); or the 5' homology arm includes the first sequence, the second sequence, the third sequence, and the fourth sequence in sequence from the 5' end to the 3' end, and the 3' homology arm includes the fifth sequence and the sixth sequence in sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the fourth sequence is the reverse complementary sequence of the fifth sequence, and the second sequence is the reverse complementary sequence of the third sequence (Figure 1B, bottom). "Reverse complementary sequence" refers to a sequence that can form at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing with another sequence after reversing the direction. For example, the first sequence, when read from the 3' end to the 5' end, can be complementary paired with the sixth sequence read from the 5' end to the 3' end according to the rules of AT and CG. The 5' homology arm and the 3' homology arm can transcribe a segment of RNA respectively, and these two segments of RNA (corresponding to the 5' homology arm and the 3' homology arm in the circularizable RNA molecule) can form a palindromic stem with a length of about 20-50 base pairs by partial complementary pairing corresponding to the second (or fifth) sequence and the third (or fourth) sequence when approaching each other, and form a hairpin structure with a missing loop portion or a palindromic arm truncated at the bend by partial complementary pairing corresponding to the first (or sixth) sequence and the sixth (or first) sequence, and the length of the complementary portion (the stem portion of the hairpin) is about 3-20 base pairs. In addition to the above complementary pairing, the portion corresponding to the fourth (or third) sequence and the fifth (or second) sequence in the transcribed RNA of the 3' homology arm (Figure 1B, top) or the 5' homology arm (Figure 1B, bottom) will also form a complete hairpin structure or palindrome, wherein the length of the stem portion of the hairpin structure is about 3-20 base pairs, the length of the loop portion is 1-15 nucleotides, and the sequence inside the loop is not complementary. "Complementary pairing" refers to base complementary pairing, that is, the bases of each nucleotide residue in the nucleic acid molecule are connected by hydrogen bonds and the like according to the corresponding relationship of AT / AU and CG. In this way, in the RNA transcribed by the vector of the present application, the portion corresponding to the 5' homology arm and the 3' homology arm, in addition to base pairing with each other to form a palindrome stem with a length of about 20-50 base pairs and a complementary pairing portion with a length of about 3-20 base pairs of missing hairpin structure or palindrome, also forms a complete hairpin structure or palindrome, and the overall structure is close to ITR, as shown in Figure 1A.Although the hairpin structure or palindrome arm on the right side of Figure 1A is incomplete, the existence of the palindrome arm on the left side and the closed state of the end of the palindrome stem (i.e., the junction of the two palindrome arms) may make the precursor RNA, especially the structure of the intron ribozyme therein, more stable, thereby improving the RNA cyclization efficiency and circular RNA yield. The 5' homology arm and 3' homology arm of the present application can use a sequence without CpG. CpG is the abbreviation of 5' cytosine (C)-phosphate (p)-guanine (G)-3'. The DNA of bacteria and the like is rich in unmethylated CpG, while the CpG in mammalian DNA is basically methylated. Unmethylated CpG can stimulate the immune system of vertebrates through TLR9, wherein TLR9 recognizes DNA with CpG, activates the signaling pathway, and causes the production of inflammatory cytokines such as IL-6 and IL-2. In order to reduce the immune response, a sequence that does not contain or is modified to remove CpG can be used. The target gene in the vector of the present application can be a protein coding gene or a non-coding gene. The target gene can be natural, synthetic or modified. The protein coding sequence can encode any protein. The protein coding sequence can encode a protein of eukaryotic or prokaryotic origin. The protein coding sequence can encode a human protein or a non-human protein. In some embodiments, the protein coding sequence can encode an antigenic protein, an antibody, or a Cas9 nuclease. In some embodiments, the protein coding sequence can encode a firefly luciferase or a long-bellied water flea luciferase. When the target gene is a non-coding gene, the circular RNA prepared by the vector can be, for example, a miRNA sponge or a non-coding RNA. The miRNA sponge can exist in the cytoplasm in the form of mRNA, adsorb numerous miRNA molecules in the cytoplasm, and play a sponge-like miRNA absorption role. Non-coding RNA refers to a single-stranded RNA that does not encode protein, which may play a regulatory role in the transcription and translation of DNA. To promote the translation of protein coding sequences in circular RNA, the vector of the present application may include an internal ribosome entry site (IRES) coding sequence on one side of the target gene, such as the 5' end. "Internal ribosome entry site" or "IRES" refers to a nucleic acid sequence that allows protein translation initiation to be independent of the 5' cap structure and can start translation from the middle of the mRNA. The IRES coding sequence may include a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a natural IRES. When the target gene is a protein coding sequence, the vector of the present application may include a spacer sequence between the 5' intron fragment and the IRES coding sequence or the target gene. In particular, the vector of the present application may also include a spacer sequence between the target gene and the 3' intron fragment. Spacer sequences refer to sequences added to prevent adjacent or neighboring, or even distant elements from interfering with each other during transcription, RNA folding, etc. Whether vector elements will interfere with each other during transcription, RNA folding, etc. can be predicted by computer software such as RNA folding software (such as RNAFold). Spacer sequences can also be designed with the aid of computer software such as RNA folding software (such as RNAFold). The vector of the present application may also include an RNA polymerase promoter upstream of the 5' homology arm for transcription of the vector. The RNA polymerase promoter may include a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a natural RNA polymerase promoter. The vector of the present application may also include a restriction endonuclease site downstream of the 3' homology arm for linearization of the vector. In the transcription of the vector, especially in vitro transcription, it is necessary to linearize the vector. The linearization of the vector can be achieved by enzyme digestion at the above-mentioned restriction endonuclease. In some embodiments, the restriction endonuclease site is unique in the vector. The circularizable RNA of the present application includes the precursor RNA prepared by the vector of the present application, which may contain, from the 5' end to the 3' end, the following in sequence: a) an optional 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an internal ribosome entry site (IRES), e) a target gene, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment containing a 5' splicing site, and h) an optional 3' homology arm; or a) an optional 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an internal ribosome entry site (IRES), e) a target gene, f) a 5' self-splicing intron fragment containing a 5' splicing site, and g) an optional 3' homology arm, wherein the target gene is a protein coding sequence, and each element is operably connected. The circularizable RNA of the present application, including the precursor RNA prepared by the vector of the present application, may contain, from the 5' end to the 3' end, in sequence: a) an optional 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a target gene, d) a 5' self-splicing intron fragment containing a 5' splicing site, and e) an optional 3' homology arm, wherein the target gene is a non-coding sequence, and each element may be operably connected. The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site in the circularizable RNA can be derived from the anthrax Bacillus recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Synechocystis tRNA-fMet gene, the intron of the Thermotoga naphthophila 23S rRNA gene, the Pseudoclase tRNA-fMet gene of Hofmannii, the ndhL and trnL-UAA genes of Synechococcus elongatus, or the Thermotoga geophyta 23S rRNA gene, and have good self-splicing ability. By truncating each intron at different sites, the corresponding RNA sequences of the 3' end intron fragment and the exon can be used as the 3' self-splicing intron fragment containing the 3' splicing site, and the corresponding RNA sequences of the 5' end exon and the intron fragment can be used as the 5' self-splicing intron fragment containing the 5' splicing site. The 3' cleavage site and the 5' cleavage site may be dinucleotides, such as AG and GU, or AC and AU, respectively. The 3' intron fragment may comprise a corresponding RNA sequence of a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 3' end fragment of a natural intron (and the 3' exon fragment). The 5' intron fragment may comprise a corresponding RNA sequence of a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the 5' end fragment of a natural intron (and the 5' exon fragment). "Corresponding RNA sequence" refers to an RNA sequence obtained by replacing T in a DNA sequence with U. A "homologous arm" in a circularizable RNA refers to an RNA sequence that is capable of forming at least about 25%, 50%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing with another RNA (e.g., another homology arm). The 5' homology arm and the 3' homology arm in the circularizable RNA can, when approaching each other, i) complement each other to form a stem-loop structure, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem portion; ii) complement each other to form a structure containing a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem portion; or iii) complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of two stem-loops, the stem portions of the two stem-loops are connected, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the palindromic stem or the loop portion of one of the stem-loops. In one embodiment, the 5' homology arm may include the first sequence and the second sequence in sequence from the 5' end to the 3' end, and the 3' homology arm may include the third sequence, the fourth sequence, the fifth sequence, and the sixth sequence in sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the second sequence is the reverse complementary sequence of the third sequence, and the fourth sequence is the reverse complementary sequence of the fifth sequence (Figure 1B, top); or the 5' homology arm includes the first sequence, the second sequence, the third sequence, and the fourth sequence in sequence from the 5' end to the 3' end, and the 3' homology arm includes the fifth sequence and the sixth sequence in sequence from the 5' end to the 3' end, wherein the first sequence is the reverse complementary sequence of the sixth sequence, the fourth sequence is the reverse complementary sequence of the fifth sequence, and the second sequence is the reverse complementary sequence of the third sequence (Figure 1B, bottom). "Reverse complementary sequence" refers to a sequence that can form at least about 25%, 50%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% base pairing with another sequence after reversing its direction. For example, the first sequence, when read from the 3' end to the 5' end, can be complementary paired with the sixth sequence read from the 5' end to the 3' end according to the rules of AU and CG. The 5' homology arm and the 3' homology arm in the circularizable RNA can, when close to each other, form a palindromic stem of about 20-50 base pairs in length by complementary pairing of the second (or fifth) sequence and the third (or fourth) sequence, and a hairpin structure with a missing loop portion or a palindromic arm truncated at the bend by complementary pairing of the first (or sixth) sequence and the sixth (or first) sequence, and the length of the complementary portion (the stem portion of the hairpin) is about 3-20 base pairs. In addition to the complementary pairing mentioned above, portions of the fourth (or third) sequence and the fifth (or second) sequence in the 3' homologous arm (Figure 1B, top) or the 5' homologous arm (Figure 1B, bottom) also form a complete hairpin structure or palindrome arm, wherein the stem portion of the hairpin structure is approximately 3-20 base pairs in length, the loop portion is 1-15 nucleotides in length, and the sequences inside the loop are not complementary. The length of the 5' spacer sequence and / or the 3' spacer sequence can be 5-70 nucleotides, and is used to prevent adjacent or neighboring, or even distant elements from interfering with each other during transcription, RNA folding, and the like. The circularizable RNA molecule of the present application can be obtained by transcription using the vector of the present application. The present application also provides a circular RNA, which can be obtained by the method for preparing circular RNA of the present application using the vector of the present application; or by treating the circularizable RNA molecule of the present application under suitable conditions, wherein the suitable conditions include the presence of GTP and magnesium ions. The length of the circular RNA can be about 500 to about 10,000 nucleotides. The present application provides a composition, which may include the single-stranded DNA molecule, double-stranded DNA molecule, vector, circularized RNA molecule of the present application, or cells containing the above-mentioned single-stranded DNA molecule, double-stranded DNA molecule, vector, or circularized RNA molecule. The composition can be used to prepare circularized RNA and / or circular RNA, especially to produce circular RNA that can translate into protein or has biological activity in vitro or in vivo in cells. Circular RNA with biological activity can be, for example, miRNA sponge or non-coding RNA. The present application also provides a composition, which may include the circular RNA molecule of the present application, or a cell containing the circular RNA molecule. The composition may be a pharmaceutical composition, and may also include a pharmaceutically acceptable carrier, excipient or diluent. A pharmaceutically acceptable carrier can be a composition other than the active ingredient (i.e., the carrier, cell, precursor RNA, or circular RNA of the present application). A pharmaceutically acceptable carrier may include, but is not limited to, a buffer, an excipient, a stabilizer, or a preservative. Examples of pharmaceutically acceptable carriers are physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delay agents, such as salts, buffers, sugars, antioxidants, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants, or emulsifiers, or combinations thereof. The amount of a pharmaceutically acceptable carrier in a pharmaceutical composition can be determined experimentally based on the activity of the carrier and the desired characteristics of the preparation, such as stability and / or minimal oxidation. In certain embodiments, the composition of the present application may include a buffer, such as acetic acid, citric acid, histidine, boric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, Tris buffer, HEPPSO, HEPES, neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, sucrose, mannose or dextran, mannitol; protein; polypeptide or amino acid, such as glycine; antioxidant; chelating agent, such as EDTA or glutathione; adjuvant (e.g., aluminum hydroxide); antibacterial and antifungal agents; and preservatives. The present application also provides the use of the composition for preparing circular RNA, or for in vivo treatment, etc. For example, in one embodiment, the present application provides a method for expressing a vaccine, a therapeutic protein, or other types of proteins in a subject in need, comprising administering the composition of the present application comprising circular RNA to the subject. The therapeutic protein may be, for example, an antibody, a fusion protein, etc. In one embodiment, the subject is a subject with a loss of a functional gene, and the circular RNA in the composition of the present application can perform the function of the RNA transcribed by the missing gene, or continuously express the protein translated by the missing gene in vivo. The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cows, horses, chickens, amphibians, and reptiles, although mammals, such as non-human primates, sheep, dogs, cats, cows and horses are preferred. When the circular RNA is translated to express a therapeutic protein or to exert a therapeutic effect, a therapeutically effective amount of a composition comprising the circular RNA is administered to the subject. The composition of the present application of a "therapeutically effective amount" preferably causes a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free symptom periods, or prevents damage or disability caused by the disease. For example, for the treatment of tumor-bearing subjects, a "therapeutically effective amount" means that, relative to untreated subjects, preferably, tumor growth is inhibited by at least about 40%, more preferably by at least about 60%, more preferably by at least about 80%, and more preferably by at least about 99%. The therapeutically effective amount of the present application fusion protein can reduce tumor volume or alleviate symptoms in a subject (usually a human, or another mammal). When necessary, the precursor RNA or circular RNA in the present application can be purified. For example, when the composition of the present application is applied to a subject, the circular RNA is preferably purified. The purification of circular RNA or precursor RNA can be carried out by applying a size exclusion column in a high performance liquid chromatography (HPLC) system. The administration of the pharmaceutical composition can be determined by a medical worker, such as a doctor, based on the specific conditions of the subject, such as gender, age, previous medical history, etc. The pharmaceutical composition of the present application can be configured for oral, intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or push). " Parenteral administration " refers to a mode different from intestinal and topical, usually by injection, including but not limited to intravenous, intramuscular, intraarterial, intramembrane, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, dura mater and intrasternal injection and push. In one embodiment, the composition can be formulated for infusion or intravenous administration. Compositions disclosed herein can be provided, for example, as a sterile liquid preparation, such as isotonic aqueous solution, emulsion, suspension, dispersion or viscous composition, which can be buffered to required pH. In some embodiments, the administration of the composition can be carried out in any way, such as by parenteral or non-parenteral administration, including by aerosol inhalation, injection, infusion, ingestion, blood transfusion, implantation or transplantation. For example, the compositions described herein can be administered to a patient via intravenous injection, intranasally, intrathecally or intraperitoneally, transarterially, intradermally, subcutaneously, intratumorally, intramedullary, intranodally, intramuscularly. The composition of the present application can be transfected into cells via, for example, liposome transfection, electroporation, or nanocarrier encapsulation. The nanocarrier can be, for example, a lipid, a polymer, or a lipid-polymer hybrid. The composition of the present application can reach the subject via a release delivery system. Release delivery systems include polymer-based systems such as polylactide-glycolide, copolyoxalate, polyesteramide, polyorthoester, polycaprolactone, polyhydroxybutyric acid and polyanhydride. Delivery systems also include non-polymer systems, which are lipids, including sterols, such as cholesterol, cholesterol esters, and fatty acids or neutral fats, such as mono- and triglycerides; peptide-based systems; hydrogel release systems; wax coatings; tablets using conventional adhesives and excipients; partially fused implants; etc. In some embodiments, lipid nanoparticles or polymers are used as delivery vehicles for therapeutic circular RNAs described herein, including delivering RNA to tissues. The pharmaceutical composition can be a sustained release agent, including implants, and microcapsule delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. See, for example, Sustained and Controlled Release Drug Delivery Systems, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978. The pharmaceutical compositions can be administered via medical devices, such as (1) needle-free subcutaneous injection devices (e.g., U.S. Pat. Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; and 4,596,556); (2) microinfusion pumps (U.S. Pat. No. 4,487,603); (3) transdermal delivery devices (U.S. Pat. No. 4,486,194); (4) push injection devices (U.S. Pat. Nos. 4,447,233 and 4,447,224); and (5) osmotic devices (U.S. Pat. Nos. 4,439,196 and 4,475,196). The compositions of the present application can be used in combination with other therapeutic agents, vaccines, etc. The combination of therapeutic agents discussed herein can be administered simultaneously as a single composition in a pharmaceutically acceptable carrier, or as separate compositions, wherein each agent is in a pharmaceutically acceptable carrier. In another embodiment, the combination of therapeutic agents can be administered sequentially. Furthermore, if multiple administrations of the combination therapy are performed, and the agents are administered sequentially, the order of sequential administration at each time point may be reversed or remain the same, sequential administration may be combined with simultaneous administration, or any combination thereof. The present application will be further described with reference to the following non-limiting examples. Example Example 1. Construction of a vector for the production of circularized RNA using inverted terminal repeats (ITRs) Adeno-associated virus (AAV) is a single-stranded DNA virus belonging to the genus Parvovirus [25-27] Recombinant AAV vectors are considered to be ideal gene therapy vectors due to their safety, high efficiency, and stability, and have been widely used in clinical applications. [28,29] The genome of the AAV vector contains an expression cassette and two inverted terminal repeats (ITRs). The ITR sequence consists of two palindromic arms (stem-loop) and a long palindromic stem. [30,31] . The inventors of the present application believe that if this highly complementary palindromic structure is applied to RNA cyclization, it may be possible to enhance the RNA's cyclization ability by shortening the distance between the RNA ends and maintaining the stability of the self-splicing intron ribozyme during the cyclization process. Therefore, based on the disclosure of Daniel G. et al.

[0021] Based on the two ITR sequences, wild-type ITR

[0031] , and ITRs without CpG motifs

[0032] , to replace the homology arms in the text, to construct a vector for preparing circularizable RNA. The strategy of constructing vectors according to Daniel G.'s publication is also called the "published strategy", while the vector construction strategy in this article is also called the "ITR strategy". According to the ITR strategy of this application, each ITR was divided into two segments, and the 3' end sequence was used as the 5' ITR, and the 5' end sequence was used as the 3' ITR, respectively replacing Daniel G. et al.

[0021] Alternatively, the 5' end sequence can be used as the 5' ITR and the 3' end sequence can be used as the 3' ITR, replacing the 5' homology arm and the 3' homology arm of Daniel G. et al.

[0021] 5' homology arm and 3' homology arm (Figure 1B, bottom). Taking the design above Figure 1B as an example, as shown in the complete ITR transcription product of Figure 1A, with the inflection point of the right palindrome arm as the boundary, the transcription product of 3'ITR includes the 5' palindrome arm and one side of the 3' palindrome arm, and the transcription product of 5'ITR includes the other side of the 3' palindrome arm. 1.1 Vector construction Refer to the published article by Daniel G.

[0021] , construct a control vector and a vector used to prepare circularizable RNA in this application. Specifically, for the construction of the control vector, a DNA fragment was synthesized, which contained, from 5' to 3' direction, the following sequence: a T7 promoter (SEQ ID NO: 1), a 5' homology arm (SEQ ID NO: 2), a 3' intron & exon E2 (SEQ ID NO: 3), a 5' spacer sequence (SEQ ID NO: 4), a CVB3IRES component (SEQ ID NO: 5), a firefly luciferase (FLUC) encoding gene (SEQ ID NO: 6), a 3' spacer sequence (SEQ ID NO: 9), a 5' intron & exon E1 (SEQ ID NO: 10), a 3' homology arm (SEQ ID NO: 11), and an EcoRV restriction enzyme site (GATATC) for plasmid linearization, wherein the intron is an Anabaena intron, and exons E1 and E2 are exon sequences required for the self-splicing function of the Anabaena intron. The synthesized DNA fragment was cloned into the pUC57 vector (SEQ ID NO: 12), and the linearized vector product was obtained by EcoRV digestion. For the vector used to prepare circularizable RNA in the present application, the construction method is the same as above, except that the 5' side homology arm and the 3' side homology arm are replaced by the 5' ITR sequence and the 3' ITR sequence, respectively. The specific structure can be seen in Figure 1B (above). The 5' ITR sequence and the 3' ITR sequence derived from the wild-type ITR are shown in SEQ ID NOs: 13 and 14, respectively, and the 5' ITR sequence and the 3' ITR sequence transformed into a CpG-free sequence are shown in SEQ ID NOs: 15 and 16, respectively. Among them, the complementary sequences in the 5' ITR and the 3' ITR are shown with underscores, and the palindrome arm formation sequence is shown in bold italics. 5'ITR and 3'ITR derived from wild type: CpG-free 5'ITR and 3'ITR: The above gene synthesis, vector construction and plasmid linearization were all completed by GenScript. 1.2 In vitro transcription The linearized plasmid vector obtained above was subjected to in vitro transcription (IVT) to obtain RNA products. Specifically, the reaction system shown in Table 1 was incubated at 37°C for 2 h, and then 2 μl of DNase I (RNase-free, ON-109, Hongene) was added, mixed, and incubated at 37°C for 30 min. Table 1. In vitro transcription reaction system 1.3 Purification of RNA by LiCl precipitation The RNA product obtained above was purified by LiCl precipitation. Specifically, 22 μl of enzyme-free water (AM9937, Thermo Fisher) and 20 μl of 8M LiCl solution (no DNase or RNase, ST498-100ml, Beyotime) were added to the IVT stock solution to make the LiCl concentration 2.5M, mixed, and incubated at -20°C for more than 30 minutes. Centrifuge at 4°C and 12000g for 15 minutes and discard the supernatant. Add 500 μl of 70% ethanol, invert to mix, centrifuge at 4°C and 12000g for 3 minutes, and discard the supernatant; repeat this step. Centrifuge at 4°C and 12000g for 1 minute, aspirate the supernatant, add 100 μl of enzyme-free water to dissolve the RNA. The concentration of purified RNA can be detected by Nanodrop ONEC micro-volume UV-visible spectrophotometer (ND-ONEC-W, Thermo scientific). 1.4 RNA Circularization The purified mRNA obtained above was subjected to cyclization treatment (one-step cyclization method). Specifically, 20 μg of purified RNA was taken, adjusted to about 0.5-2 μg / μl with enzyme-free water, incubated at 70°C for 5 min, and then immediately placed on ice for 3 min. GTP (100 mM) was added to a final concentration of 2 mM, and Mg was added. 2+ T4 RNA ligase buffer (10x) (B0216S, NEB), Mg 2+ The final concentration was 10 mM. Incubate at 55°C for 8 min. The product was purified by LiCl precipitation as described above, and the concentration of the purified RNA was detected by Nanodrop. 1.5 Gel electrophoresis analysis Take the purified circularized RNA product and pass it through E-Gel TM EX gel electrophoresis was used for analysis. Specifically, 150-200 ng of purified RNA was taken and adjusted to 10 μl with enzyme-free water, followed by addition of 10 μl of gel loading buffer II (AM8546G, ThermoFisher) and mixing. TM EX agarose gel (2%, G401002, ThermoFisher), remove the comb, put the gel into the gel slot of the electrophoresis system, and add 20μl of the mixed sample to the gel wells one by one. Set the electrophoresis time to 10-20min and start electrophoresis. After the electrophoresis is completed, open the filter and cool for 5-10min. Use E-Gel TM The image acquisition system of the EX equipment (G8300, ThermoFisher) was used to observe the electrophoresis results and collect pictures. In E-Gel TMIn the EX gel electrophoresis gel diagram, it is usually shown that the circular RNA has the slowest swimming speed, the precursor linear RNA has the second fastest swimming speed, and the open-loop RNA (nicked circular RNA) has the fastest speed. The RNA cyclization effect prepared according to the published strategy and the ITR strategy of this application is shown in Figure 1C. Specifically, the circular RNA bands prepared by the ITR strategy of this application are purer, with no obvious residual precursor linear RNA bands, no interference from other bands, and the content of open-loop RNA by-products is also lower (the bottom band in the figure), indicating that the ITR construction strategy can improve the purity of circular RNA and reduce the content of open-loop RNA by-products. 1.6 Capillary gel electrophoresis In order to detect the circularization efficiency of RNA, the RNA before and after circularization was subjected to capillary gel electrophoresis experiment using Agilent 5200 fragment analyzer (M53100AA, Agilent) and Agilent DNF-471 RNA kit (15nt, DNF-471-0500, Agilent). Specifically, take the purified RNA in 1.3 and 1.4, adjust the concentration to 50-100 ng / μl with enzyme-free water, and then place it at 80°C for 2 min together with RNA molecular weight standard (RNA Ladder). After the reaction, immediately place it on a 4°C ice box for instant cooling. Add 22 μL of diluent standard (RNA diluent standard), 2 μL of the sample to be tested and RNA molecular weight standard to the sample plate, and refer to the Agilent 5200 fragment analyzer manual for specific equipment operation methods to perform capillary electrophoresis experiments. The results are shown in Figure 1D. From the band size, it can be seen that the in vitro transcription product band before circularization is slightly larger than the circular RNA band after circularization, because the linear precursor RNA contains self-splicing intron sequences, and the introns are cut off during the circularization process to become free intron fragments. In addition, the circular RNA band of the published strategy contains an uncircularized precursor RNA band above, while there is no obvious precursor residual band above the circular RNA produced by the ITR strategy (the samples were not digested with RNase R, because RNase R can specifically eliminate linear RNA). It can be seen that ITR is better than the homology arm in the published strategy in its ability to close the distance between the two ends of mRNA to assist in the circularization reaction, and is a more ideal circularization strategy. 1.7 Sequencing of circularized RNA The RNA obtained in 1.4 was subjected to reverse transcription, PCR, and gel recovery, and the position of the circularized linker was sequenced. use II First-strand cDNA Synthesis Kit (+gDNA Removal Agent) (R212-01, Novozyme) was used to reverse transcribe the product obtained by the above in vitro self-splicing reaction. Specifically, the reaction system was configured as shown in Table 2, pipetted and mixed, and heated at 42°C for 2 minutes. Table 2. Reverse transcription reaction system Then, 4 μl of 5×HiScript II qRT SuperMix II was added to the above mixture, mixed by pipetting, and incubated at 50°C for 15 min and 85°C for 5 sec. After reverse transcription, the obtained cDNA was added to the PCR reaction system shown in Table 3, mixed by pipetting, and PCR reaction was performed according to the procedure shown in Table 4. Table 3. PCR reaction system Table 4. PCR program settings All reaction products were recovered by electrophoresis, and the target band was cut out by a blue light gel cutter (OSE-470L, Tiangen Biochemical Technology Co., Ltd.). Gel recovery was performed using the Gel Recovery Kit (D2500-01 / D2500-02, Omega) according to the instructions. The recovered products were sent for Sanger sequencing, and the sequences of the circularized adapter sequencing primers were SEQ ID NOs: 26 and 27. The sequencing result of the RNA circularization junction position is shown in SEQ ID NO: 29, and the sequences of the 3' spacer sequence, E1, E2 and 5' spacer sequence are represented by bold italics, underline, italics, and bold underline, respectively. It can be seen that the intron has been removed and E1 and E2 are connected together. Example 2. Screening of introns with in vitro self-splicing ability Currently, mainstream RNA circularization is based on the self-splicing of class I and class II introns. In order to obtain more efficient RNA circularization, self-splicing introns are screened. First, in order to obtain an intron with in vitro self-splicing ability, the EGFP coding sequence (SEQ ID NO: 8, used as a nonsense sequence to detect intron splicing) was truncated and loaded onto both ends of the candidate intron ( FIG. 2A ). Specifically, the synthetic DNA sequence comprises, from 5' to 3' end, a T7 promoter (SEQ ID NO: 1), a 5' EGFP coding sequence (SEQ ID NO: 17), a recA gene from Bacillus Anthraci to be screened, a 23S ribosomal RNA gene from Coxiella burnetii, a tRNA-fMet gene from Scytonema hofmanii, a 23S ribosomal RNA gene-2 ​​from Coxiella burnetii (Coxiella burnetii) (another gene fragment of the 23S ribosomal RNA gene from Coxiella burnetii), a tRNA-fMet gene from Synechocystis sp., a 23S rRNA gene from Thermotoga naphthophila, a 23S rRNA gene from Synechococcus elongatus. elongatus) ndhL and trnL-UAA genes, the introns & exons of the 23S rRNA gene of Thermotoga subterranea or the trnL gene of Phormidium sp. (SEQ ID NO: 18-22 and SEQ ID NO: 59-62), and the 3'EGFP coding sequence (SEQ ID NO: 23). The synthesized gene fragments were cloned into the pUC57 vector (SEQ ID NO: 12). Gene synthesis, vector construction, and plasmid linearization were all completed by GenScript. Refer to 1.2 to 1.5, and perform in vitro transcription, circularization condition treatment (for intron splicing), and E-Gel TM EX gel electrophoresis can be used to preliminarily determine whether an intron cleavage reaction has occurred. At the same time, agarose gel electrophoresis can be used to more directly determine whether an intron cleavage reaction has occurred. The method is as follows: Take the above-purified circularized RNA product and uncircularized RNA and analyze them by agarose gel electrophoresis. Specifically, take 100-150ng of purified RNA, adjust it to 9μl with enzyme-free water, then add 1μl10* dye (GenScript) and mix well. Take out the agarose gel (1%, GenScript) and put it into the electrophoresis tank. The electrophoresis solution covers the gel wells, and 10μl of the mixed sample is added to the gel wells in turn. Set the voltage to 220V, the electrophoresis time to 8-10min, and start electrophoresis. After the electrophoresis is completed, use the image acquisition system that comes with the multifunctional gel image analysis system (Tanon-1600R) to observe the electrophoresis results and collect pictures. In agarose gel electrophoresis, it is usually shown that the migration speed slows down as the mass increases. The mass of RNA that has been sheared is smaller than that of RNA that has not been sheared, so the appearance of bands one after the other in the figure indicates that shearing has occurred. The results are shown in Figures 2B and 2C. Eight of the nine introns, namely those from Bacillus anthracis, Coxiella burnetii, Synechocystis, Thermotoga naphthophilum, Synechococcus elongatus, Pseudoclase hofmannii, and Thermotoga geophyta, underwent self-cleavage. TM EX gel electrophoresis showed a shorter splicing band (Figure 2B) and agarose gel showed tandem bands (Figure 2C), while the intron from Pholiota did not undergo self-splicing reaction, indicating that it does not have the ability of self-splicing in vitro. Referring to the method steps of 1.7, the purified RNA obtained by referring to 1.4 was reverse transcribed, PCR and gel recovered, and the circularized junction position was sequenced. The primers used for PCR were SEQ ID NOs: 24 and 25, and the sequencing of the circularized junction also used the primers shown in SEQ ID NOs: 24 and 25. The sequencing results of the transcribed circularized RNA from the plasmid containing the introns of Pseudomonas, Coxiella burnetii, Bacillus anthracis, Synechocystis, Thermotoga naphthyrophila, Coxiella burnetii-2, Pseudoclase algae, Synechococcus elongatus and Thermotoga geophyta were shown as SEQ ID NOs: 30-34 and SEQ ID NOs: 63-66, respectively, wherein the two EGFP coding sequence fragments are shown in bold, the sequences of the two exons are shown in underline and italics, respectively, and the introns are shown in italics and underline. It can be seen that the eight introns that underwent self-splicing reactions have been successfully removed, while the unspliced ​​introns of the Plectranthus schrenkiana were connected to the truncated GFP coding sequence fragment, indicating that the four introns except the Plectranthus schrenkiana intron all have the ability to self-splicing in vitro. Example 3. Intron-assisted circularization test Class I intron-mediated mRNA circularization is mainly achieved by breaking the intron sequence at a specific site and adding it to both sides of the desired circularization sequence (GOI). In the subsequent RNA circularization process, the introns on both sides of the GOI form a ribozyme structure, self-cleave and connect the GOI into a ring. Different intron segmentation sites may affect the formation of its ribozyme structure and affect the final splicing efficiency. In this example, the 8 introns selected in Example 2 were segmented at different sites and screened for splicing efficiency. The segmentation positions P of the 8 introns are marked one by one by uppercase bold underlines in SEQ ID NOs: 18-21 and SEQ ID NOs: 59-62 in Table 7, and the segmentation is specifically performed after the P point. The sequences of the 3' intron & exon E2 and the 5' intron & exon E1 formed after segmentation are summarized in Table 5. Table 5. Intron segmentation sites and open reading frame (ORF) sequences in constructed vectors With reference to Example 1 and FIG. 1B , the vector was constructed using the ITR strategy of the present application. Specifically, a synthetic DNA sequence, which sequentially comprises from 5' to 3' direction: T7 promoter (SEQ ID NO: 1), 5' ITR sequence without CpG (SEQ ID NO: 13), 3' intron & exon E2 (see the segmentation site in Table 5), 5' spacer sequence (SEQ ID NO: 4), CVB3IRES component (SEQ ID NO: 5), firefly luciferase (FLUC), Daphnia pulex luciferase (GLUC) encoding gene (SEQ ID NO: 6 or 7), 3' spacer sequence (SEQ ID NO: 9), 5' intron & exon E1 (see the segmentation site in Table 5), 3' ITR sequence without CpG (SEQ ID NO: 14), and restriction site EcoRV (GATATC) for plasmid linearization. The above-mentioned synthetic DNA fragment was cloned into pUC57 vector (SEQ ID NO: 12) to obtain a linearized vector product. The control vector was constructed according to the published strategy, and the specific structure was the same as described in 1.1, except that the FLUC encoding gene was replaced by the EGFP encoding gene (SEQ ID NO: 8). Gene synthesis, vector construction and plasmid linearization were all completed by GenScript. Then in vitro transcription, circularization, and capillary gel electrophoresis are performed. For specific steps, see 1.2, 1.3, 1.4, and 1.6. Capillary gel electrophoresis results of some transcription products are shown in Figures 3A-3F. None of the samples were digested with RNase R. Since RNase R can specifically eliminate linear RNA, researchers usually display the purity percentage after RNase R digestion. Constructions with very low cyclization ability can also eliminate linear RNA precursors and other linear byproducts through RNase R to obtain purer circular RNA, but this display method will conceal the cyclization ability of the construction itself. Constructions with low cyclization ability will result in much higher consumption of process reagents than constructions with high efficiency, and the yield of circular RNA will be greatly reduced. The purity of circular RNA was calculated based on the results of capillary gel electrophoresis, and the results are listed in Table 6. Table 6. Purity of circular RNA obtained at each intron cleavage point It can be seen that the introns with better cyclization effects and their disconnection patterns include Synechocystis P3, Coxiella burnetii P4, Thermotoga naphthophilum P1, Bacillus anthracis P2, Bacillus anthracis P3, Coxiella burnetii-2P1, Coxiella burnetii-2P2, Pseudoclase algae P3, Synechococcus elongatus P1, Thermotoga geophyta P2 and Thermotoga geophyta P3 (Figures 3B-3L), which are significantly better than 59.5% of Anabaena (Figure 3A). The purified RNA was subjected to reverse transcription, PCR, gel recovery, and sequencing of the circularized linker position, as described in 1.7. The primer pairs used in PCR amplification and sequencing were SEQ ID NOs: 27 and 26, or SEQ ID NOs: 27 and 28, or SEQ ID NOs: 91 and 92. The sequencing results show that each intron is removed, leaving exons at both ends. Exemplary circularized adapter sequencing results, including circularized adapter sequencing results of Coxiella burnetii P4, Bacillus anthracis P3, Synechocystis P1, Thermotoga naphthophila P1, Coxiella burnetii-2 P1, Pseudoclase algae P3, Synechococcus elongatus P1, and Thermotoga geophyta P2, are shown in SEQ ID NOs: 35-38 and SEQ ID NOs: 93-96, respectively, wherein the sequences of the 3' spacer sequence, E1, E2, and 5' spacer sequence are represented by bold, underline, italics, and bold underline, respectively. Example 4. Co-transcriptional cyclization The intron from Bacillus anthracis has a greatly enhanced autocatalytic cleavage ability when truncated at P3, allowing the mRNA to undergo an autonomous cyclization reaction at the same time as transcription is completed, without the need for an additional cyclization step. In other words, RNA transcription and cyclization can be completed in 1.2. Specifically, the control vector and the vector containing the truncated intron P3 of Bacillus anthracis in Example 3 were constructed, and in vitro transcription was performed according to 1.2. The obtained RNA was purified according to 1.3, and then capillary gel electrophoresis was performed according to 1.6. The results of capillary gel electrophoresis are shown in Figures 4A and 4B. When the Bacillus anthracis intron was used and truncated at P3, the purity of circular RNA reached 71.5% (Figure 4B), while the control vector did not produce circular RNA after transcription, and the proportion of linear RNA reached 89.6% (Figure 4A). Referring to step 1.7, the circular RNA was reverse transcribed, PCR and gel recovered, and the circularized junction was sequenced. When the anthrax intron was used and truncated at P3, the sequencing result was the same as SEQ ID NO: 36, indicating that the transcribed RNA was successfully circularized under only the method steps of step 1.2, without the circularization process of step 1.4. Co-transcriptional cyclization is a very promising method for producing circular RNA, which plays a very important role in solving yield problems and reducing process residue risks. Table 7. List of some sequences involved in this application Although the present application has been described in conjunction with one or more embodiments, it should be understood that the present application is not limited to these embodiments. The description in this application is intended to cover all variant forms and equivalents, all included in the subject matter and scope of the appended claims. All documents cited in this article are fully incorporated herein by reference. References 1. Baden, LR et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). 2.Walsh,E.E.et al.Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates.N.Engl.J.Med.383,2439–2450(2020). 3.Kaczmarek,J.C.,Kowalski,P.S.&Anderson,D.G.Advances in the delivery of RNA therapeutics:from concept to clinical reality.Genome Med.9,60(2017). 4.Holtkamp,S.et al.Modification of antigen-encoding RNA increases stability,translational efficacy,and T-cell stimulatory capacity of dendritic cells.Blood 108,4009–4017(2006). 5.Kuhn,A.N.et al.Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.Gene Ther.17,961–971(2010). 6.Presnyak,V.et al.Codon optimality is a major determinant of mRNA stability.Cell 160,1111–1124(2015). 7.Kariko,K.,Muramatsu,H.,Ludwig,J.&Weissman,D.Generating the optimal mRNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleoside-modified,protein-encoding mRNA.Nucleic Acids Res.39,e142–e142(2011). 8.Jeck,W.R.&Sharpless,N.E.Detecting and characterizing circular RNAs.Nat.Biotechnol.32,453–461(2014). 9.Barrett,S.P.&Salzman,J.Circular RNAs:analysis,expression and potential functions.Development 143,1838–1847(2016). 10.Hansen,T.B.et al.Natural RNA circles function as efficient microRNA sponges.Nature 495,384–388(2013). 11.Li,Z.et al.Exon-intron circular RNAs regulate transcription in the nucleus.Nat.Struct.Mol.Biol.22,256–264(2015) 12.Chen,L.-L.&Yang,L.Regulation of circRNA biogenesis.RNA Biol.12,381–388(2015). 13.Jeck,W.R.&Sharpless,N.E.Detecting and characterizing circular RNAs.Nat.Biotechnol.32,453–461(2014). 14.Wang,Y.&Wang,Z.Efficient backsplicing produces translatable circular mRNAs.RNA 21,172–179(2015). 15.Legnini,I.et al.Circ-ZNF609is a circular RNA that can be translated and functions in myogenesis.Mol.Cell 66,22–37.e9(2017). 16.Pamudurti,N.R.et al.Translation of CircRNAs.Mol.Cell 66,9–21.e7(2017).17.Enuka,Y.et al.Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor.Nucleic Acids Res.44,1370–1383(2016). 18.Cech,T.R.1990.Self-splicing of group I introns.Annu.Rev.Biochem.59:543–568. 19.Saldanha,R.,G.Mohr,M.Belfort,and A.M.Lambowitz.1993.Group I and group II introns.FASEB J.7:15–24 20.Jacquier,A.1996.Group II introns:elaborate ribozymes.Biochimie 78:474–487. 21.Wesselhoeft,R.A.,Kowalski,P.S.&Anderson,D.G.Engineering circular RNA for potent and stable translation in eukaryotic cells.Nat.Commun.9,2629(2018). 22.Chen R,Wang SK,Belk JA,Amaya L,Li Z,Cardenas A,Abe BT,Chen CK,Wender PA,Chang HY.Engineering circular RNA for enhanced protein production.Nat Biotechnol.2023 Feb;41(2):262-272. 23.Chen,C.,Wei,H.,Zhang,K.,Li,Z.,Wei,T.,Tang,C.,Yang,Y.,&Wang,Z.(2022).A flexible,efficient,and scalable platform to produce circular RNAs as new therapeutics.bioRxiv. 24.Qiu,Z.,Zhao,Y.,Hou,Q.,Zhu,J.,Zhai,M.,Li,D.,Li,Y.,Liu,C.,Li,N.,Cao,Y.,Yang,J.,Sun,Z.,&Zuo,C.(2022).Clean-PIE:a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression.bioRxiv 25.Atchison RW,Casto BC,Hammon WM.Adenovirus-associated defective virus particles.Science 1965;149:754–6.[PubMed:14325163]. 26.Carter BJ.Adeno-associated virus and the development of adeno-associated virus vectors:a historical perspective.Mol Ther 2004;10(6):981–9.[PubMed:15564130]. 27.Flotte TR,Berns KI.Adeno-associated virus:a ubiquitous commensal of mammals.Hum Gene Ther 2005;16(4):401–7.[PubMed:15871671]. 28.Maguire AM,Simonelli F,Pierce EA et al:Safety and efficacy of gene transfer for Leber’s congenital amaurosis.N Engl J Med,2008;358(21):2240–48. 29.Bainbridge JW,Smith AJ,Barker SS et al:Effect of gene therapy on visual function in Leber’s congenital amaurosis N Engl J Med,2008;358(21):2231–39. 30.Wilmott P,Lisowski L,Alexander IE,Logan GJ.A User’s Guide to the Inverted Terminal Repeats of Adeno-Associated Virus.Human gene therapy methods 2019;30(6):206–213.[PubMed:31752513] 31.Duan D,Yan Z,Yue Y,Engelhardt JF.Structural analysis of adeno-associated virus transduction intermediates.Virology 1999;261(1):8–14.[PubMed:10484751]. 32.Pan X,Yue Y,Boftsi M,Wasala LP,Tran NT,Zhang K,Pintel DJ,Tai PWL,Duan D.Rational engineering of a functional CpG-free ITR for AAV gene therapy.Gene Ther.2022 Jun;29(6):333-345.

Claims

1. A single-stranded DNA molecule comprising, from the 5' end to the 3' end, a) a 3' self-splicing intron fragment comprising a 3' splicing site and b) a 5' self-splicing intron fragment comprising a 5' splicing site, wherein each element is operably linked, The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are derived from the introns of the recA gene of Bacillus Anthraci., the 23S ribosomal RNA gene of Coxiella burnetii., the tRNA-fMet gene of Scytonema hofmanii, the tRNA-fMet gene of Synechocystis sp., the 23S rRNA gene of Thermotoga naphthophila., the ndhL and trnL-UAA genes of Synechococcus elongatus or the 23S rRNA gene of Thermotoga subterranea.

2. The single-stranded DNA molecule according to claim 1, wherein an intron of the Bacillus anthracis recA gene comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18; an intron of the Coxiella burnetii 23S ribosomal RNA gene comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 19 or 59; an intron of the Synechocystis tRNA-fMet gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 20; an intron of the Thermotoga naphthophilum 23S rRNA gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:21; an intron of the Pseudoclaena hofmannii tRNA-fMet gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:60; The introns of the Synechococcus elongatus ndhL and trnL-UAA genes comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:61; or An intron of the Thermotoga geophila 23S rRNA gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:

62.

3. The single-stranded DNA molecule according to claim 1 or 2, wherein the 3' self-splicing intron fragment comprising the 3' splicing site and the 5' self-splicing intron fragment comprising the 5' splicing site are obtained by truncating SEQ ID NO: 18 after the 133rd, 195th or 294th nucleotide of SEQ ID NO: 18; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO: 19 after the 100th, 157th, 206th or 245th nucleotide of SEQ ID NO: 19; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO: 20 after the 112th, 246th, 298th, 393rd or 500th nucleotide of SEQ ID NO: 20; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO: 21 after the 130th, 314th, 369th or 408th nucleotide of SEQ ID NO: 21; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO:59 after the 313th or 453rd nucleotide of SEQ ID NO:59; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO: 60 after the 71st, 140th, 184th or 216th nucleotide of SEQ ID NO: 60; The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO:61 after the 135th or 186th nucleotide of SEQ ID NO:61; or The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are obtained by truncating SEQ ID NO: 62 after the 94th, 336th, 492nd or 577th nucleotide of SEQ ID NO:

62.

4. The single-stranded DNA molecule of any one of claims 1 to 3, wherein the 3' self-splicing intron fragment comprising the 3' splicing site and the 5' self-splicing intron fragment comprising the 5' splicing site respectively comprise i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: 5 NO:77 and 78, xvii) SEQ ID NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 having a nucleotide sequence with at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity. 5 . The single-stranded DNA molecule according to claim 1 , further comprising a target gene between a 3′ self-splicing intron fragment comprising a 3′ splicing site and a 5′ self-splicing intron fragment comprising a 5′ splicing site. The single-stranded DNA molecule of claim 5 , wherein the target gene is a protein coding sequence or a non-coding sequence.

7. The single-stranded DNA molecule according to any one of claims 1 to 6, further comprising a 5' homology arm at the 5' end of the 3' self-splicing intron fragment comprising the 3' splicing site, and a 3' homology arm at the 3' end of the 5' self-splicing intron fragment comprising the 5' splicing site.

8. The single-stranded DNA molecule of claim 7, wherein the sequences of the 5' homology arm and the 3' homology arm are complementary to form a stem-loop structure, wherein: The 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem; The sequences of the 5' homology arm and the 3' homology arm are complementary to each other to form a structure comprising a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent at the palindromic stem portion; or The sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of the two stem-loops, the stem portions of the two stem-loops are connected, and wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent to the palindromic stem or the loop portion of one of the stem-loops.

9. The single-stranded DNA molecule of claim 7 or 8, wherein the 5' homology arm and / or the 3' homology arm contain no CpG sequence.

10. The single-stranded DNA molecule according to any one of claims 5 to 9, further comprising an internal ribosome entry site (IRES) coding sequence between the 3' self-splicing intron fragment comprising the 3' splicing site and the target gene.

11. The single-stranded DNA molecule of claim 10, wherein the IRES is selected from the group consisting of Coxsackievirus B3 (CVB3), Coxsackievirus A (CVB1 / 2), Taura syndrome virus, blood-sucking assassin bug virus, Theile's encephalomyelitis virus, simian virus 40, fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea looper-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian Encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, classical swine fever virus, human FGF2, human SFTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, salivary virus, Coxsackie virus, double echovirus, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, IRESs for Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivell disease virus, and eIF4G aptamer. 12 . The single-stranded DNA molecule according to claim 10 , further comprising a 5′ spacer sequence between the 3′ self-splicing intron fragment comprising the 3′ splicing site and the IRES coding sequence. 13 . The single-stranded DNA molecule according to claim 5 , further comprising a 3′ spacer sequence between the target gene and the 5′ self-splicing intron fragment comprising the 5′ splicing site.

14. The single-stranded DNA molecule of claim 12 or 13, wherein the length of the 5' spacer sequence and / or the 3' spacer sequence is at least 10 nucleotides.

15. The single-stranded DNA molecule according to any one of claims 7 to 14, further comprising an RNA polymerase promoter upstream of the 5' homology arm.

16. The single-stranded DNA molecule according to claim 15, wherein the RNA polymerase promoter is an RNA polymerase promoter derived from T7 virus, T6 virus, SP6 virus, T3 virus or T4 virus.

17. The single-stranded DNA molecule according to any one of claims 1 to 16, comprising: a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splice site, c) a 5' spacer sequence, d) an internal ribosome entry site encoding sequence, e) a protein coding sequence, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment containing a 5' splice site, and h) a 3' homology arm; or a) 5' homology arm, b) 3' self-splicing intron fragment containing 3' splicing site, c) non-coding sequence, d) 5' self-splicing intron fragment containing 5' splicing site and e) 3' homology arm.

18. A double-stranded DNA molecule comprising i) the single-stranded DNA molecule according to any one of claims 1 to 17, and ii) a second strand complementary to the single-stranded DNA molecule.

19. A vector for preparing circular RNA, comprising the single-stranded DNA molecule according to any one of claims 1 to 17 or the double-stranded DNA molecule according to claim 18.

20. A method for preparing circular RNA, comprising i) in vitro transcribing a precursor RNA from the vector of claim 19 under suitable conditions, and ii) incubating the precursor RNA under suitable conditions, wherein the suitable conditions in step ii) include the presence of magnesium ions and guanosine triphosphate.

21. A method for preparing a circular RNA molecule, comprising subjecting the vector of claim 19 to in vitro transcription under suitable conditions, wherein the 3' self-splicing intron fragment containing a 3' splicing site and the 5' self-splicing intron fragment containing a 5' splicing site in the vector comprise nucleotide sequences having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NOs: 41 and 42 or SEQ ID NOs: 43 and 44, respectively, wherein the suitable conditions include the presence of magnesium ions and nucleoside triphosphates.

22. A circularizable RNA molecule, which comprises, from the 5' end to the 3' end, in sequence: a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a 5' spacer sequence, d) an internal ribosome entry site, e) a protein coding sequence, f) a 3' spacer sequence, g) a 5' self-splicing intron fragment containing a 5' splicing site, and h) a 3' homology arm; or a) a 5' homology arm, b) a 3' self-splicing intron fragment containing a 3' splicing site, c) a non-coding sequence, d) a 5' self-splicing intron fragment containing a 5' splicing site, and e) a 3' homology arm, The 3' self-splicing intron fragment containing the 3' splicing site and the 5' self-splicing intron fragment containing the 5' splicing site are derived from the introns of the anthrax Bacillus recA gene, the Coxiella burnetii 23S ribosomal RNA gene, the Pseudomonas hoffmannii tRNA-fMet gene, the Synechocystis tRNA-fMet gene, the Thermotoga naphthophilum 23S rRNA gene, the Synechococcus elongatus ndhL and trnL-UAA genes or the Thermotoga geophys 23S rRNA gene.

23. The circularizable RNA molecule of claim 22, wherein the 3' self-splicing intron fragment comprising the 3' splicing site and the 5' self-splicing intron fragment comprising the 5' splicing site are respectively composed of i) SEQ ID NOs: 41 and 42, ii) SEQ ID NOs: 43 and 44, iii) SEQ ID NOs: 47 and 48, iv) SEQ ID NOs: 75 and 76, v) SEQ ID NOs: 39 and 40, vi) SEQ ID NOs: 49 and 50, vii) SEQ ID NOs: 51 and 52, viii) SEQ ID NOs: 53 and 54, ix) SEQ ID NOs: 55 and 56, x) SEQ ID NOs: 57 and 58, xi) SEQ ID NOs: 67 and 68, xii) SEQ ID NOs: 69 and 70, xiii) SEQ ID NOs: 71 and 72, xiv) SEQ ID NOs: 73 and 74, xv) SEQ ID NOs: 45 and 46, xvi) SEQ ID NOs: NO:77 and 78, xvii) SEQ ID NO:79 and 80, xviii) SEQ ID NO:81 and 82, xix) SEQ ID NO:83 and 84, xx) SEQ ID NO:85 and 86, xxi) SEQ ID NO:87 and 88 or xxii) SEQ ID NO:89 and 90 are transcribed from a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.

24. The circularizable RNA molecule of claim 22 or 23, wherein the sequences of the 5' homology arm and the 3' homology arm are complementary to form a stem-loop structure, wherein: The 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent in the stem; The sequences of the 5' homology arm and the 3' homology arm are complementary to each other to form a structure comprising a palindromic stem and a stem-loop, wherein the palindromic stem is connected to the stem portion of the stem-loop, wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent at the palindromic stem portion; or The sequences of the 5' homology arm and the 3' homology arm can complement each other to form a structure containing a palindromic stem and two stem-loops, wherein the palindromic stem is connected to the stem portions of the two stem-loops, the stem portions of the two stem-loops are connected, and wherein the 5' end of the 5' homology arm and the 3' end of the 3' homology arm are adjacent to the palindromic stem or the loop portion of one of the stem-loops.

25. The circularizable RNA molecule according to any one of claims 22 to 24, which is transcribed from the vector according to claim 19.

26. A circular RNA molecule obtained by transcription from the vector of claim 19, prepared by the method of claim 20 or 21, or circularized by the circularizable RNA molecule of any one of claims 22 to 25.

27. Use of an intron derived from the recA gene of Bacillus anthracis, the 23S ribosomal RNA gene of Coxiella burnetii, the tRNA-fMet gene of Synechocystis, the tRNA-fMet gene of Pseudoclase hofmannii, the 23S rRNA gene of Thermotoga naphthophilum, the ndhL and trnL-UAA genes of Synechococcus elongatus or the 23S rRNA gene of Thermotoga geogensis in the preparation of a vector for preparing circular RNA.

28. The use according to claim 27, wherein an intron of the Bacillus anthracis recA gene comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18; an intron of the Coxiella burnetii 23S ribosomal RNA gene comprising a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 19 or 59; an intron of the Synechocystis tRNA-fMet gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 20; an intron of the Thermotoga naphthophilum 23S rRNA gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:21; an intron of the Pseudoclaena hofmannii tRNA-fMet gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:60; The introns of the Synechococcus elongatus ndhL and trnL-UAA genes comprise a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:61; or An intron of the Thermotoga geophila 23S rRNA gene comprises a nucleotide sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:

62.

29. A host cell comprising the single-stranded DNA molecule of any one of claims 1-17, the double-stranded DNA molecule of claim 18, the vector of claim 19, the circularizable RNA molecule of any one of claims 22-25, or the circular RNA molecule of claim 26.

30. A method for screening introns with self-splicing ability, comprising: i) providing a double-stranded DNA molecule, which comprises, from the 5' end to the 3' end, a promoter, a first sequence, a 5' natural adjacent exon of an intron to be screened or a sequence corresponding to the natural adjacent exon, an intron to be screened, a 3' natural adjacent exon of an intron to be screened or a sequence corresponding to the natural adjacent exon, and a second sequence; ii) transcribing the double-stranded DNA molecule in step i) to obtain an RNA molecule; iii) treating the RNA molecule of step ii) under suitable conditions, said suitable conditions comprising the presence of magnesium ions and guanosine triphosphate; and iv) analyzing whether the RNA molecule treated in step iii) contains the transcription product sequence of the intron to be screened, wherein the absence of the transcription product sequence of the intron to be screened in the RNA molecule treated in step iii) indicates that the intron to be screened is an intron with self-splicing ability.

31. The method of claim 30, wherein the transcription in step ii) is performed by in vitro transcription.

32. The method of claim 30 or 31, wherein the analysis of step iv) comprises: Reversely transcribing the RNA molecule treated in step iii) into a single-stranded DNA molecule, and sequencing the single-stranded DNA molecule or sequencing the RNA molecule treated in step iii), wherein the absence of the sequence of the intron to be screened indicates that the intron to be screened is an intron with self-splicing ability; Reversely transcribe the RNA molecule treated in step iii) into a single-stranded DNA molecule, convert the single-stranded DNA molecule into a double-stranded DNA molecule, and compare the length of the double-stranded DNA molecule with the length of the double-stranded DNA molecule in step i), wherein the length of the double-stranded DNA molecule is shorter than that of the double-stranded DNA molecule in step i), indicating that the intron to be screened is an intron with self-splicing ability; or Comparing the migration speed of the RNA molecule in step ii) with that of the RNA molecule treated in step iii) in gel electrophoresis, wherein the migration speed of the RNA molecule treated in step iii) is greater than that of the RNA molecule in step ii), indicates that the intron to be screened is an intron with self-splicing ability.

Citation Information

Patent Citations

  • Osmotic drug delivery system

    US4439196A

  • Variable flow implantable infusion apparatus

    US4447224A

  • Medication infusion pump

    US4447233A

  • Instrument for locating faults in aircraft passenger reading light and attendant call control system

    US4475196A

  • Therapeutic device for administering medicaments through the skin

    US4486194A

Cited By

  • Vector used for preparing circular RNA containing few non-target sequences, and method

    WO2025247180A1

  • Vector and method for preparing circular RNA

    WO2026184713A1